[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Chinese PLA General Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":630},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,160,0,25,[9,46,73,99,129,157,179,206,230,246,271,299,338,363,392,410,433,458,479,506,526,545,566,588,608],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100651612","photon-counting-ct-versus-conventional-ct-for-carotid-plaque-assessment-in-patients-with-carotid-artery-stenosis-100651612",false,"NCT07762664","Photon-Counting CT Versus Conventional CT for Carotid Plaque Assessment in Patients With Carotid Artery Stenosis","Prospective Comparison of Photon-Counting Detector CT and Conventional Energy-Integrating Detector CT for Carotid Atherosclerotic Plaque Assessment in Patients With Carotid Artery Stenosis","Inclusion Criteria:\n\n* Age 18 years or older.\n* Patients with carotid atherosclerotic plaque or carotid artery stenosis.\n* Patients scheduled to undergo carotid artery stenting.\n* Patients undergoing preprocedural carotid CTA examination.\n* Ability to provide written informed consent.\n\nExclusion Criteria:\n\n* Known allergy to iodinated contrast material.\n* Severe renal insufficiency or other contraindications to contrast-enhanced CT.\n* Pregnancy or suspected pregnancy.\n* Severe motion or other artifacts resulting in nondiagnostic image quality.\n* Incomplete clinical or imaging data.","ALL","10 Years","90 Years",{"count":21,"type":22},100,"ESTIMATED","OBSERVATIONAL","This prospective observational study aims to compare photon-counting detector computed tomography angiography (PCD-CTA) with conventional energy-integrating detector computed tomography angiography (EID-CTA) for the assessment of carotid atherosclerotic plaques in patients with carotid artery stenosis.",[26,27,28],"Carotid Artery Stenosis","Carotid Atherosclerosis","Carotid Atherosclerotic Plaque",[30,26,31,32],"Photon-Counting CT","Plaque Characterization","Carotid Plaque","RECRUITING","2026-08-19",{"date":36,"type":37},"2026-08-20","ACTUAL",{"date":39,"type":37},"2026-01-07",{"date":41,"type":22},"2029-01-07",{"name":43,"class":44},"Chinese PLA General Hospital","OTHER",1,{"id":47,"slug":48,"hasResults":12,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":12,"sex":17,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":58,"briefSummary":60,"conditions":61,"keywords":64,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":67,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":45},"100632534","phase-2-venetoclax-azacitidine-in-combination-with-chidamide-and-cag-in-fit-older-patients-with-acute-myeloid-leukaemia-100632534","NCT07514936","Venetoclax-Azacitidine in Combination With Chidamide and CAG in Fit Older Patients With Acute Myeloid Leukaemia","Venetoclax-Azacitidine in Combination With Chidamide and CAG Versus 3+7 Regimen in Fit Older Patients With Acute Myeloid Leukaemia：A Multicenter, Randomized, Controlled, Phase 3 Trial","Inclusion Criteria:\n\n1. Voluntary participation in the clinical study; the subject or legal guardian fully understands and is informed about the study and has signed the Informed Consent Form (ICF); willing to follow and able to complete all trial procedures;\n2. Age between 60-75 years at the time of screening, with no gender restrictions;\n3. Patients are newly diagnosed with AML, and the diagnosis conforms to the standards of the Chinese Medical Association 2021 edition;\n4. No severe allergic constitution;\n5. Liver function: ALT and AST \\\u003C= 2.5 times the upper limit of normal values, bilirubin \\\u003C= 2 times the upper limit of normal values;\n6. Renal function: creatinine \\\u003C= upper limit of normal values;\n7. No uncontrollable infections or severe mental illnesses;\n8. Performance status score is 0-3 (ECOG), with an expected survival of at least 4 months.\n\nExclusion Criteria:\n\n1. Patients who are allergic to the study medication or have contraindications to it;\n2. Pregnant or breastfeeding women;\n3. Patients with active infections;\n4. Patients with long-term smoking or alcohol abuse that could affect the evaluation of trial results;\n5. Patients with mental disorders or other conditions that prevent obtaining informed consent, or who are unable to cooperate with the treatment and examination procedures;\n6. Patients who have undergone major organ surgery within the last 6 weeks;\n7. Abnormal liver function, with total bilirubin \\> 1.5 times the upper limit of normal, ALT\u002FAST \\> 2.5 times the upper limit of normal, or liver-infiltrated patients with ALT\u002FAST \\> 5 times the upper limit of normal; abnormal renal function, with serum creatinine \\> 1.5 times the upper limit of normal;\n8. Patients whom the investigator deems unsuitable for this clinical trial (e.g., poor compliance, drug abuse, etc.).","60 Years","75 Years",{"count":56,"type":22},120,"INTERVENTIONAL",[59],"PHASE3","This study is a multicenter, prospective, randomized, controlled clinical trial, observing the efficacy and safety of the CACAG+Venetoclax regimen (Chidamide + Azacitidine + Aclarubicin + Cytarabine + Recombinant Human Granulocyte Colony-Stimulating Factor + Venetoclax) in elderly patients with newly diagnosed Acute Myeloid Leukemia (AML). The control group applies the standard \"3+7\" regimen. The aim is to improve the remission rate of AML patients, reduce the probability of adverse events, and thereby improve patient prognosis and extend patient survival.",[62,63],"Newly Diagnosed Acute Myeloid Leukemia (AML)","Elderly Patients",[63,65,66],"newly diagnosed","Acute Myeloid Leukemia",{"date":36,"type":37},{"date":69,"type":37},"2024-11-18",{"date":71,"type":22},"2027-12-31",{"name":43,"class":44},{"id":74,"slug":75,"hasResults":12,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":12,"sex":17,"minAge":81,"maxAge":82,"enrollmentInfo":83,"targetDuration":4,"studyType":57,"phases":85,"briefSummary":87,"conditions":88,"keywords":4,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":4},"100650182","leap-strategy-for-neovascular-age-related-macular-degeneration-100650182","NCT07744204","LEAP Strategy for Neovascular Age-Related Macular Degeneration","Laser-Enhanced Anti-VEGF Precise Penetration (LEAP) Strategy for Neovascular Age-Related Macular Degeneration: A Multicentre, Prospective, Stratified Block-Randomised Controlled Trial","LEAP","Inclusion Criteria:\n\n* Age ≥ 50 years, male or female\n* Diagnosed with neovascular age-related macular degeneration (nAMD) based on multimodal imaging (fundus photography, OCT, FFA, ICGA), including type 1, type 2, or type 3 MNV, or PCV\n* Clear ocular media and adequate pupillary dilation to permit OCT, fundus photography, angiography, and laser photocoagulation\n* Active MNV in the study eye at least partially located ≥ 300 μm from the foveal centre\n* Willing and able to provide written informed consent\n* Only one eye per subject enrolled; if both eyes eligible, the study eye is selected by the investigator\n\nExclusion Criteria:\n\n* Active MNV entirely located within 300 μm of the foveal centre\n* Significant hemorrhage obscuring the active MNV lesion on FFA\u002FICGA Unwilling or unable to provide informed consent, refusal of randomization, or inability to complete scheduled follow-up visits\n* Concurrent participation in other clinical trials\n* Contraindication or allergy to FFA\u002FICGA\n* Coexisting ocular conditions that may affect visual acuity during follow-up (e.g., cataract, diabetic retinopathy, retinal vascular occlusion, uveitis, neovascular glaucoma)\n* Severe ocular surface infection (e.g., conjunctivitis, severe blepharitis)\n* Uncontrolled hypertension (blood pressure \\> 180\u002F110 mmHg) despite antihypertensive therapy\n* Any condition in the study eye or systemically that, in the investigator's opinion, would pose significant risk to the participant\n* Poorly controlled blood glucose in diabetic patients\n* Transient ischemic attack, stroke, myocardial infarction, acute congestive heart failure, or other acute cardiovascular event requiring hospitalization within the past 4 months","50 Years","99 Years",{"count":84,"type":22},240,[86],"NA","Background: Age-related macular degeneration (AMD) is a common eye disease that can cause blindness in older adults. The \"wet\" form of AMD, called neovascular AMD, happens when abnormal blood vessels grow under the retina and leak fluid. The current standard treatment requires repeated eye injections of anti-VEGF drugs, often every month or every few months. This frequent injection schedule is a heavy burden for patients and many cannot keep up with the treatment plan.\n\nPurpose: This study tests whether a single session of low-intensity laser applied to the diseased area, given just before the anti-VEGF injection, can help the drug reach the target more effectively. If this works, patients may need far fewer injections over time.\n\nIntervention: Participants will be randomly assigned to one of two groups. The experimental group will receive the laser treatment followed by an anti-VEGF injection within 6 hours. The control group will receive the anti-VEGF injection alone, according to the current standard regimen. Four different anti-VEGF drugs are allowed in this study: conbercept, aflibercept, ranibizumab, and faricimab.\n\nParticipants: The study plans to enroll at least 240 patients with active neovascular AMD across five hospitals in China. All participants must be at least 50 years old and meet specific eligibility criteria.\n\nFollow-up: All participants will be followed for 24 months with monthly clinic visits. The study will record the total number of injections received, changes in vision, fluid status on eye scans, and any side effects.\n\nPrimary Outcome: The main measure is the total number of anti-VEGF injections each participant needs over the 24-month period. The study will compare the experimental group and the control group to see whether the laser-enhanced approach reduces the injection frequency.",[89,90],"Neovascular Age-related Macular Degeneration(nAMD)","Wet Macular Degeneration","NOT_YET_RECRUITING","2026-08-18",{"date":34,"type":37},{"date":95,"type":22},"2026-08-01",{"date":97,"type":22},"2029-07-31",{"name":43,"class":44},{"id":100,"slug":101,"hasResults":12,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":4,"eligibilityCriteria":105,"healthyVolunteers":12,"sex":17,"minAge":106,"maxAge":54,"enrollmentInfo":107,"targetDuration":4,"studyType":57,"phases":109,"briefSummary":111,"conditions":112,"keywords":114,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":45},"100652564","phase-1-in-vivo-cd19cd20-car-t-cell-therapy-for-relapsedrefractory-b-cell-lymphoma-100652564","NCT07775508","In Vivo CD19\u002FCD20 CAR T-Cell Therapy for Relapsed\u002FRefractory B-Cell Lymphoma","A Clinical Study on the Safety of in Vivo- CAR-T Cell Immunotherapy Targeting CD19\u002FCD20 for the Treatment of Relapsed\u002FRefractory B-cell Lymphoma","Inclusion Criteria:\n\n* 1\\. The subject voluntarily agrees to participate in the study, has signed the informed consent form, and is willing and able to comply with the scheduled visits, study treatment, laboratory tests, and other study procedures.\n\n  2\\. Patients with B-cell lymphoma confirmed by cytological or histopathological examination according to the 2022 World Health Organization classification, meeting all of the following criteria:\n  1. Lymphoma cells are confirmed to express CD19 and\u002For CD20 antigens by immunophenotyping or immunohistochemical examination.\n  2. Eligible B-cell lymphomas include:\n\n     * Aggressive B-cell lymphomas, including large B-cell lymphoma (LBCL), Burkitt lymphoma (BL), and mantle cell lymphoma (MCL);\n     * Indolent B-cell lymphomas, including chronic lymphocytic leukemia\u002Fsmall lymphocytic lymphoma (CLL\u002FSLL), follicular lymphoma (FL), marginal zone lymphoma (MZL), lymphoplasmacytic lymphoma (LPL), and hairy cell leukemia (HCL).\n  3. Relapsed or refractory B-cell lymphoma, defined as follows:\n\n     * Relapse: The patient has received adequate prior therapy and previously achieved a complete response (CR) or partial response (PR) after first-line systemic therapy (which must include an anti-CD20 monoclonal antibody and an anthracycline-containing chemotherapy regimen), second-line or subsequent systemic therapy, or autologous hematopoietic stem cell transplantation (ASCT), but relapsed after the completion of treatment, with disease progression confirmed by cytology or histology;\n     * Refractory: The patient failed to achieve CR or PR after first-line systemic therapy, or had no response to the most recent second-line or subsequent systemic therapy regimen, with progressive disease (PD) or stable disease (SD) as a best response of treatment.\n  4. The patient must have at least one measurable lesion. If salvage therapy was administered after ASCT, the patient must have no response to the most recent salvage therapy or must have relapsed after the most recent salvage therapy. Patients with relapsed indolent lymphoma may be enrolled only if clinical indications for treatment are present, such as symptomatic mass lesions, organ compression, cytopenias, or B symptoms.\n\n  3\\. Male or female subjects aged 18-75 years, inclusive. 4. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2. 5. Estimated life expectancy of more than 3 months from the date of signing the informed consent form.\n\n  6\\. Absolute neutrophil count≥1×10\\^9\u002FL, platelet count≥75×10\\^9\u002FL, hemoglobin≥60g\u002FL.\n\n  7\\. Adequate renal, hepatic, cardiac, and pulmonary function, defined as follows:\n  1. Creatinine clearance (estimated by the Cockcroft-Gault formula) ≥60 mL\u002Fmin;\n  2. Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST)≤2.5×upper limit of normal (ULN), total bilirubin≤1.5×ULN;\n  3. Cardiac ejection fraction≥50%, no pericardial effusion on echocardiography, and no significant abnormalities on electrocardiogram (ECG);\n  4. No clinically significant pleural effusion, and oxygen saturation \\>92% on room air at baseline.\n\n  8\\. Subjects agree to use effective contraception from the time of signing the informed consent form until 1 year after cell infusion.\n\nExclusion Criteria:\n\n* 1\\. The patient has severe cardiac dysfunction, or left ventricular ejection fraction (LVEF) \\\u003C50%, or a history within the 12 months prior to enrollment of myocardial infarction, coronary angioplasty or coronary stent implantation, unstable angina, clinically significant arrhythmia, or other severe cardiovascular diseases.\n\n  2\\. A history of severe pulmonary dysfunction or severe pulmonary disease associated with impaired lung function.\n\n  3\\. The patient has a history of malignancies other than B-cell lymphoma, and is ineligible unless they have been disease-free and have not received any form of antineoplastic therapy for at least 3 consecutive years.\n\n  4\\. Severe active infection that cannot be effectively controlled. 5. The patient has severe autoimmune disease, congenital immunodeficiency or active autoimmune disease requiring ongoing treatment, or is currently within the washout period after having received medications that may affect CAR-T cell immunotherapy, or is anticipated to require medications during the study period that may affect CAR-T cell immunotherapy treatment.\n\n  6\\. The patient has tuberculosis infection, active hepatitis B virus (HBV) infection, active hepatitis C virus (HCV) infection, or human immunodeficiency virus (HIV) infection; has received a live vaccine within 4 weeks, or is anticipated to require a live vaccine during the study period.\n\n  7\\. The patient has previously undergone allogeneic hematopoietic stem cell transplantation, solid organ allogeneic transplantation, or allogeneic cell therapy.\n\n  8\\. A history of severe allergic reactions to biological products, including antibiotics.\n\n  9\\. The patient has other significant uncontrolled comorbidities that may affect protocol compliance or interpretation of results.\n\n  10\\. The investigator judges that the patient is unlikely to complete all visits and procedures required by the study protocol (including medium- and long-term follow-up visits), such as insufficient willingness of the patient and their family members to participate in the study, refusal to participate, inability of the patient to fully cooperate with the study arrangements, or inadequate compliance on the part of the patient and their family members.\n\n  11\\. Any other severe physical or psychiatric disorder or clinically significant laboratory abnormality that may increase the risk associated with study participation, interfere with the interpretation of study results, or, in the investigator's judgment, make the patient unsuitable for participation in the study.","18 Years",{"count":108,"type":22},18,[110],"PHASE1","This Phase 1, open-label, single-arm, dose-escalation study is designed to evaluate the safety and tolerability of SL1617 Injection in patients with relapsed or refractory B-cell lymphoma. SL1617 is an investigational in vivo CAR T-cell immunotherapy targeting CD19 and CD20, utilizing an engineered lentiviral vector to generate functional CAR-T cells in vivo without the need for ex vivo cell processing or lymphodepletion. Participants will receive a single intravenous infusion of SL1617 using a traditional 3+3 dose-escalation design. The planned starting dose is 1.0 × 10\\^9 transducing units (TU), followed by dose levels of 3.0 × 10\\^9 TU and 6.0 × 10\\^9 TU. Dose escalation will be guided by the occurrence of dose-limiting toxicities (DLTs).",[113],"B-cell Lymphoma",[115,116,117,118,119,120,121],"in vivo CAR-T","CD19","CD20","SL1617","lentiviral vector","immunotherapy","B-cell lymphoma","2026-08-17",{"date":36,"type":37},{"date":125,"type":37},"2026-06-01",{"date":127,"type":22},"2029-01-01",{"name":43,"class":44},{"id":130,"slug":131,"hasResults":12,"nctId":132,"briefTitle":133,"officialTitle":134,"acronym":135,"eligibilityCriteria":136,"healthyVolunteers":12,"sex":17,"minAge":106,"maxAge":137,"enrollmentInfo":138,"targetDuration":140,"studyType":23,"phases":4,"briefSummary":141,"conditions":142,"keywords":147,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":150,"lastUpdatePostDateStruct":151,"startDateStruct":152,"completionDateStruct":154,"leadSponsor":156,"locationsCount":45},"100652467","cold-region-exposure-and-cardiac-remodeling-after-pci-100652467","NCT07773870","Cold-Region Exposure and Cardiac Remodeling After PCI","Association of Cumulative Cold-Region Exposure With Left Ventricular Remodeling and Cardiovascular Outcomes After Percutaneous Coronary Intervention: A Multicenter Prospective Observational Cohort Study","COLD-PCI","Inclusion Criteria:\n\n* Age 18 to 75 years. Angiographically confirmed coronary artery disease treated with successful percutaneous coronary intervention, defined as residual stenosis \\\u003C30% with final TIMI grade 3 flow.\n\nClinically stable after PCI. Expected survival of at least 12 months. Able and willing to undergo baseline cardiovascular magnetic resonance imaging and baseline and 6-month transthoracic echocardiography.\n\nAble to provide residential, occupational, training\u002Fdeployment, and other relevant exposure histories for the 3 years preceding PCI.\n\nWritten informed consent provided.\n\nExclusion Criteria:\n\n* Severe valvular heart disease, cardiomyopathy, congenital heart disease, or other major structural heart disease.\n\nPrevious coronary artery bypass grafting or heart transplantation. End-stage heart failure or New York Heart Association class IV heart failure. Severe renal dysfunction, defined as estimated glomerular filtration rate \\\u003C30 mL\u002Fmin\u002F1.73 m².\n\nKnown contraindication to cardiovascular magnetic resonance imaging or gadolinium-based contrast agents.\n\nInability to complete transthoracic echocardiographic assessment. Inability to reliably recall or verify major residential or occupational exposure history during the 3 years preceding PCI.\n\nMore than five major changes in primary residence during the 3 years preceding PCI that preclude reliable estimation of cumulative cold-region exposure.","80 Years",{"count":139,"type":22},400,"12 Months","This multicenter prospective observational cohort study aims to investigate the association between cumulative cold-region exposure and adverse left ventricular remodeling and cardiovascular outcomes in patients with coronary artery disease undergoing successful percutaneous coronary intervention (PCI).\n\nIndividual-level chronic cold exposure will be quantified primarily by cumulative months of residence, work, or other relevant exposure in cold regions during the 3 years preceding PCI. Additional exposure measures will include regional cold-wave days derived from meteorological records and winter outdoor occupational exposure.\n\nParticipants will undergo baseline cardiovascular magnetic resonance (CMR), echocardiography, electrocardiography, and clinical and laboratory assessment after PCI. Echocardiography will be repeated at 6 months to assess left ventricular remodeling. Cardiovascular events will be prospectively collected during follow-up.\n\nThe study will evaluate whether cumulative cold-region exposure is associated with distinct CMR phenotypes, adverse left ventricular remodeling, and major adverse cardiovascular events (MACE), and whether cold-exposure measures provide incremental prognostic information beyond conventional clinical, imaging, and electrocardiographic risk markers.",[143,144,145,146],"Coronary Artery Disease","Percutaneous Coronary Intervention (PCI)","Left Ventricular Remodeling","Cold Exposure",[145,148,146,149],"Cardiac Magnetic Resonance Imaging","Acute Myocardial Infarction","2026-08-16",{"date":34,"type":37},{"date":153,"type":37},"2026-06-30",{"date":155,"type":22},"2028-12-30",{"name":43,"class":44},{"id":158,"slug":159,"hasResults":12,"nctId":160,"briefTitle":161,"officialTitle":162,"acronym":4,"eligibilityCriteria":163,"healthyVolunteers":12,"sex":17,"minAge":106,"maxAge":164,"enrollmentInfo":165,"targetDuration":167,"studyType":23,"phases":4,"briefSummary":168,"conditions":169,"keywords":171,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":174,"startDateStruct":176,"completionDateStruct":177,"leadSponsor":178,"locationsCount":45},"100651540","photon-counting-cardiac-ct-in-post-pci-patients-100651540","NCT07763340","Photon-Counting Cardiac CT in Post-PCI Patients","Diagnostic Performance and Prognostic Value of Multiparametric Photon-Counting Cardiac CT in Patients With Prior Coronary Stent Implantation: A Prospective Cohort Study","Inclusion Criteria:\n\n1. Age 18 years or older;\n2. History of percutaneous coronary intervention with implantation of at least one coronary stent;\n3. Ability to undergo iodinated contrast-enhanced CT;\n4. Ability and willingness to provide written informed consent.\n\nExclusion Criteria:\n\n1. Estimated glomerular filtration rate below the institutional threshold for contrast-enhanced CT, generally less than 30 mL\u002Fmin\u002F1.73 m², unless examination is clinically justified and approved according to institutional policy;\n2. Known severe hypersensitivity to iodinated contrast material that cannot be adequately managed using the institutional premedication protocol; Pregnancy or suspected pregnancy;\n3. Inability to provide informed consent or comply with study procedures;\n4. Severe respiratory inability to perform the required breath-hold.","100 Years",{"count":166,"type":22},800,"3 Years","This study takes patients who have undergone percutaneous coronary intervention as the research subjects and employs a prospective observational cohort design, aiming to develop and validate a \"one-stop\" photon-counting computed tomography imaging framework. The one-stop PCCT protocol implies that multiple assessments are acquired through a single examination, including coronary CT angiography for stent and native artery evaluation, resting first-pass myocardial iodine distribution imaging, and delayed myocardial extracellular volume quantification, with cardiac cine imaging performed in a prespecified dose-controlled substudy.",[170],"Cardiovascular Diseases",[172,30,170],"Radiology","2026-08-10",{"date":175,"type":37},"2026-08-13",{"date":39,"type":37},{"date":41,"type":22},{"name":43,"class":44},{"id":180,"slug":181,"hasResults":12,"nctId":182,"briefTitle":183,"officialTitle":183,"acronym":4,"eligibilityCriteria":184,"healthyVolunteers":12,"sex":185,"minAge":186,"maxAge":187,"enrollmentInfo":188,"targetDuration":4,"studyType":57,"phases":190,"briefSummary":191,"conditions":192,"keywords":194,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":198,"lastUpdatePostDateStruct":199,"startDateStruct":201,"completionDateStruct":203,"leadSponsor":205,"locationsCount":45},"100578933","clinical-study-on-prostate-thermal-vapor-ablation-guided-by-mritrus-fusion-imaging-100578933","NCT06817733","Clinical Study on Prostate Thermal Vapor Ablation Guided by MRI\u002FTRUS Fusion Imaging","Inclusion Criteria:\n\n* Age 45-85 years;\n* International Prostate Symptom Score (IPSS) ≥ 8, indicating moderate to severe Lower Urinary Tract Symptoms (LUTS) that significantly impact quality of life;\n* Poor response to pharmacological treatment or refusal of pharmacological treatment;\n* Prostate volume 30-80 mL;\n* Maximum urinary flow rate (Qmax) \\\u003C 15 mL\u002Fs;\n* Post-void residual urine volume (PVR) \\\u003C 300 mL;\n* Willingness to provide informed consent and participate in postoperative follow-up.\n\nExclusion Criteria:\n\n* Prostate volume \\\u003C 30 mL or \\> 80 mL;\n* Severe urinary tract infection;\n* Preoperative definitive diagnosis of prostate cancer;\n* Known neurogenic bladder, detrusor muscle weakness, urethral stricture, or other non-BPH causes of urinary obstruction;\n* Patients with prostatitis;\n* History of invasive prostate interventions, such as radiofrequency ablation, laser therapy, or microwave treatment;\n* Patients with severe cardiovascular disease, chronic obstructive pulmonary disease, severe diabetes, hepatic or renal dysfunction, or systemic bleeding disorders, as assessed by the investigator to be unsuitable for surgery.","MALE","45 Years","85 Years",{"count":189,"type":22},30,[86],"Objective of the Clinical Trial\n\nThe objective of this clinical trial is to preliminarily assess the feasibility and safety of performing precise prostate thermal vapor ablation under MRI\u002FTURS guidance. The primary questions it aims to address are:\n\nCan precise prostate thermal vapor ablation under MRI\u002FTURS guidance effectively treat benign prostatic hyperplasia (BPH) and alleviate lower urinary tract symptoms (LUTS)? What safety issues may arise in participants after undergoing prostate thermal vapor ablation? Study Procedures Participants Preoperative Evaluation: Participants will undergo comprehensive preoperative assessments, including clinical examinations and laboratory tests.\n\nProcedure: Participants will receive precise prostate thermal vapor ablation under MRI\u002FTURS guidance.\n\nPostoperative Follow-up:\n\nRegular follow-up to reassess prostate volume. Periodic completion of the International Prostate Symptom Score (IPSS) questionnaire.\n\nRegular measurement of maximum urinary flow rate (Qmax) and post-void residual urine volume (PVR).\n\nResearch Team The research team will conduct precise prostate thermal vapor ablation under MRI\u002FTURS guidance for the participants and manage their follow-up assessments.",[193],"Benign Prostatic Hyperplasia (BPH)",[195,196,197],"Benign prostatic hyperplasia","Rezum","MRI-TRUS","2026-08-09",{"date":200,"type":37},"2026-08-11",{"date":202,"type":37},"2025-04-15",{"date":204,"type":22},"2027-06-30",{"name":43,"class":44},{"id":207,"slug":208,"hasResults":12,"nctId":209,"briefTitle":210,"officialTitle":211,"acronym":4,"eligibilityCriteria":212,"healthyVolunteers":12,"sex":17,"minAge":213,"maxAge":164,"enrollmentInfo":214,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":216,"conditions":217,"keywords":219,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":223,"startDateStruct":225,"completionDateStruct":227,"leadSponsor":229,"locationsCount":4},"100650181","the-impact-of-preoperative-depression-on-postoperative-delirium-in-elderly-chinese-patients-a-retrospective-multicenter-observational-study-100650181","NCT07744282","The Impact of Preoperative Depression on Postoperative Delirium in Elderly Chinese Patients: A Retrospective Multicenter Observational Study","Preoperative Depression and Postoperative Delirium in Older Chinese Adults: A Multicenter Retrospective Cohort Study","Inclusion Criteria:\n\n* 1\\. Age ≥ 65 years, both genders 2. Elective non-cardiac major surgery 3. Completed preoperative depression assessment (PHQ-9) 4. Completed postoperative delirium assessment (3D-CAM)\n\nExclusion Criteria:\n\n* 1\\. History of neurological or psychiatric disorders or use of neuropsychiatric medications 2. Impaired cognitive function or inability to complete preoperative follow-up 3. Transferred to ICU postoperatively 4. Missing delirium outcome data","65 Years",{"count":215,"type":22},8000,"This study is a retrospective analysis of a large-scale multicentre prospective cohort study that investigates the impact of preoperative depression on the incidence of postoperative delirium among elderly Chinese patients undergoing non-cardiac major surgery.",[218],"Cohort Studies",[220,221,222],"Depression","Postoperative Delirium","Non-cardiac major surgery",{"date":224,"type":37},"2026-08-04",{"date":226,"type":22},"2026-08-15",{"date":228,"type":22},"2027-03-01",{"name":43,"class":44},{"id":231,"slug":232,"hasResults":12,"nctId":233,"briefTitle":234,"officialTitle":235,"acronym":4,"eligibilityCriteria":236,"healthyVolunteers":12,"sex":17,"minAge":213,"maxAge":164,"enrollmentInfo":237,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":238,"conditions":239,"keywords":4,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":242,"startDateStruct":243,"completionDateStruct":244,"leadSponsor":245,"locationsCount":4},"100650129","preoperative-anxiety-and-depression-among-older-chinese-patients-100650129","NCT07744295","Preoperative Anxiety and Depression Among Older Chinese Patients","Preoperative Anxiety and Depression Among Older Chinese Patients: A Multicenter Cross-sectional Study","Inclusion Criteria:\n\n* 1\\. Elderly patients (age ≥65 years) 2. Undergoing elective non-cardiac major surgery with a planned overnight hospital stay following surgery 3. Cognitive ability: Conscious, no severe cognitive impairment (MMSE score ≥24), able to cooperate with scale assessment\n\nExclusion Criteria:\n\n* 1\\. Patients who refuse to participate in the study 2. Patients with severe dementia, language disorder, severe hearing or visual impairment, or cognitive impairment preventing assessment 3. Patients whose surgeries were canceled 4. History of previous severe mental illness (schizophrenia, bipolar disorder) or long-term use of psychotropic medications 5. Patients admitted to ICU immediately after surgery 6. Patients who did not complete the scale assessment",{"count":215,"type":22},"A multicenter, cross-sectional study to characterize the clinical profiles of the Chinese elderly population and to determine the prevalence of preoperative anxiety and depression.",[220,240,63,241],"Anxiety","Non-cardiac Major Surgery",{"date":224,"type":37},{"date":226,"type":22},{"date":228,"type":22},{"name":43,"class":44},{"id":247,"slug":248,"hasResults":12,"nctId":249,"briefTitle":250,"officialTitle":251,"acronym":4,"eligibilityCriteria":252,"healthyVolunteers":12,"sex":17,"minAge":106,"maxAge":4,"enrollmentInfo":253,"targetDuration":4,"studyType":57,"phases":255,"briefSummary":257,"conditions":258,"keywords":261,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":264,"lastUpdatePostDateStruct":265,"startDateStruct":266,"completionDateStruct":268,"leadSponsor":270,"locationsCount":4},"100650118","phase-2-obinutuzumab-beta-combined-with-low-dose-glucocorticoid-in-new-onset-anca-associated-glomerulonephritis-100650118","NCT07746180","Obinutuzumab Beta Combined With Low-dose Glucocorticoid in New-onset ANCA-Associated Glomerulonephritis","Obinutuzumab Beta Combined With Low-dose Glucocorticoid in New-onset ANCA-Associated Glomerulonephritis: A Prospective Exploratory Study","Inclusion Criteria:\n\n* New diagnosis of ANCA-associated vasculitis (Granulomatosis with polyangiitis \\[GPA\\] or Microscopic polyangiitis \\[MPA\\]) according to the Chapel Hill Consensus Conference definitions.\n* Positive for PR3-ANCA or MPO-ANCA.\n* Active renal involvement indicated by recent renal biopsy (pauci-immune necrotizing and\u002For crescentic glomerulonephritis) OR active urine sediment characterized by glomerular hematuria and proteinuria.\n* Provided signed informed consent.\n\nExclusion Criteria:\n\n* Prior treatment with targeted B-cell therapies (e.g., Rituximab) or standard cyclophosphamide, azathioprine, or mycophenolate mofetil for AAV.\n* Current requirement for dialysis, or history of dialysis.\n* Presence of life-threatening acute vasculitis manifestations other than renal involvement (e.g., diffuse alveolar hemorrhage, respiratory failure, bowel perforation, cerebral vasculitis).\n* History of malignancy within the past 5 years.\n* Coexisting multisystem autoimmune diseases (e.g., systemic lupus erythematosus, anti-GBM disease).\n* Active severe infections, active tuberculosis, or chronic viral infections (HBV with positive HBsAg or HBV-DNA, active HCV, HIV).\n* Pregnant or lactating women.",{"count":254,"type":22},20,[256],"PHASE2","This study is an open-label, single-arm, exploratory study designed to evaluate the efficacy and safety of Obinutuzumab beta combined with a rapid-tapering glucocorticoid regimen in patients with new-onset ANCA-associated glomerulonephritis (AAGN).",[259,260],"ANCA-Associated Glomerulonephritis (AAGN)","ANCA-Associated Vasculitis (AAV)",[259,262,263],"Obinutuzumab beta","Glucocorticoid","2026-07-30",{"date":224,"type":37},{"date":267,"type":22},"2026-07-31",{"date":269,"type":22},"2029-03-30",{"name":43,"class":44},{"id":272,"slug":273,"hasResults":12,"nctId":274,"briefTitle":275,"officialTitle":275,"acronym":276,"eligibilityCriteria":277,"healthyVolunteers":12,"sex":17,"minAge":106,"maxAge":186,"enrollmentInfo":278,"targetDuration":280,"studyType":23,"phases":4,"briefSummary":281,"conditions":282,"keywords":286,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":291,"lastUpdatePostDateStruct":292,"startDateStruct":294,"completionDateStruct":296,"leadSponsor":298,"locationsCount":45},"100648650","multicenter-validation-of-the-2025-classification-criteria-for-axial-spondyloarthritis-100648650","NCT07724847","Multicenter Validation of the 2025 Classification Criteria for Axial Spondyloarthritis","MVAS2025","Inclusion Criteria:\n\n* 1\\. Presence of current chronic back pain with duration ≥3 months and without a definitive diagnosis 2. Age at onset of back pain ≤45 years 3. Presentation to a rheumatologist for evaluation of suspected axial spondyloarthritis or related conditions, without a confirmed diagnosis of axSpA or other rheumatic diseases 4. Willingness to complete comprehensive diagnostic assessments including clinical history, physical examination, CRP testing, HLA-B27 testing, pelvic X-ray, and sacroiliac joint MRI (recent imaging may be acceptable if completed within appropriate timeframe) 5. Voluntary participation with provision of signed electronic informed consent\n\nExclusion Criteria:\n\n* 1\\. Inability to communicate due to cognitive impairment, visual impairment, or other factors affecting self-assessment 2. Confirmed diagnosis of axial spondyloarthritis (axSpA), ankylosing spondylitis (AS), or other established rheumatic diseases (e.g., rheumatoid arthritis, psoriatic arthritis) 3. Back pain duration \\\u003C3 months or age at onset \\>45 years 4. Refusal or inability to complete full diagnostic evaluation due to medical contraindications (e.g., metallic implants preventing MRI, severe hepatic or renal dysfunction precluding laboratory testing) 5. Presence of clearly identified non-SpA causes of chronic back pain with established diagnosis, including lumbar disc herniation, spinal stenosis, spinal tumors, infectious spondylitis, or osteoporotic fractures 6. Failure to provide informed consent, inability to cooperate with study follow-up, or inability to provide complete data",{"count":279,"type":22},247,"1 Month","This study aims to validate the 2025 ASAS-SPARTAN revised classification criteria for axial spondyloarthritis (axSpA) in the Chinese population through a multicenter, prospective, cross-sectional observational study.\n\nAxial spondyloarthritis is a chronic inflammatory disease primarily affecting the spine and sacroiliac joints, causing back pain and stiffness. Early and accurate diagnosis is essential for timely treatment and improved patient outcomes. The 2025 ASAS-SPARTAN revised classification criteria were recently developed by the Assessment of SpondyloArthritis International Society (ASAS) and the SpondyloArthritis Research and Treatment Network (SPARTAN) to improve diagnostic accuracy and reduce over-diagnosis, with preset targets of sensitivity ≥75% and specificity ≥90%. However, the original validation study included only 71 Chinese patients out of 1,015 total participants, and racial differences in susceptibility genes, living environments, and socioeconomic-cultural backgrounds may affect the criteria's performance in Chinese patients.\n\nThis study will enroll patients with chronic back pain (CBP) lasting ≥3 months and onset age ≤45 years from multiple hospitals in China. All participants will undergo comprehensive diagnostic assessments including clinical history, physical examination, CRP testing, HLA-B27 testing, pelvic X-ray, and sacroiliac joint MRI. The 2025 ASAS-SPARTAN criteria will be applied to evaluate diagnostic performance, and results will be compared with the 2009 ASAS classification criteria and clinicians' gold-standard diagnoses.\n\nThe primary objective is to validate the sensitivity, specificity, and internal scoring rationality of the 2025 ASAS-SPARTAN criteria in Chinese axSpA patients. The secondary objective is to assess the concordance between the 2025 and 2009 ASAS criteria and analyze reasons for any discrepancies.\n\nThe findings will provide evidence for Chinese clinicians to select appropriate classification tools, reduce over-diagnosis of axSpA, and alleviate the burden on the healthcare system.",[283,284,285],"Axial Spondyloarthritis (AxSpA)","Spondyloarthritis (SpA)","Chronic Back Pain",[287,288,289,290],"Classification Criteria","Validation","Diagnostic Accuracy","ASAS-SPARTAN","2026-07-21",{"date":293,"type":37},"2026-07-24",{"date":295,"type":37},"2026-04-10",{"date":297,"type":22},"2027-04-10",{"name":43,"class":44},{"id":300,"slug":301,"hasResults":12,"nctId":302,"briefTitle":303,"officialTitle":304,"acronym":4,"eligibilityCriteria":305,"healthyVolunteers":12,"sex":17,"minAge":106,"maxAge":137,"enrollmentInfo":306,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":308,"conditions":309,"keywords":312,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":330,"lastUpdatePostDateStruct":331,"startDateStruct":332,"completionDateStruct":334,"leadSponsor":336,"locationsCount":337},"100648799","helicobacter-pylori-infection-status-and-pathological-features-for-predicting-gastric-cancer-biological-behavior-and-prognosis-a-real-world-observational-study-100648799","NCT07724496","Helicobacter Pylori Infection Status and Pathological Features for Predicting Gastric Cancer Biological Behavior and Prognosis: A Real-World Observational Study","A Multicenter Retrospective and Prospective Real-World Observational Study of Helicobacter Pylori Infection Status and Pathological Features of Early Gastric Cancer for Predicting Biological Behavior and Prognosis Across Gastric Cancer Subtypes","Inclusion Criteria:\n\n* Adults aged 18 to 80 years\n* Retrospectively identified or prospectively enrolled patients with early gastric cancer, high-grade intraepithelial neoplasia, or other gastric neoplastic lesions treated with or scheduled for endoscopic submucosal dissection according to standard clinical indications at participating medical centers\n* Availability or planned availability of sufficient Helicobacter pylori assessment data for study classification, including 13C-urea breath test, serum Helicobacter pylori IgG antibody testing, pathological assessment of gastric tissue, prior H. pylori infection history, prior eradication history, eradication confirmation, or follow-up H. pylori testing results when available\n* Availability or planned availability of gastric tissue pathological assessment from routine biopsy specimens and\u002For endoscopic submucosal dissection specimens for evaluation of tissue-based H. pylori detection, background mucosal changes, lesion pathological characteristics, and ESD-related pathological findings\n* Availability or planned availability of key clinical, endoscopic, and pathological information required to evaluate gastric cancer subtype, biological behavior, and curability after ESD, including lesion location, histological subtype, differentiation, depth of invasion, lymphovascular invasion, margin status, curative resection status, and additional treatment information when available\n* Availability of follow-up data for retrospectively included participants, or willingness and ability to participate in follow-up evaluations for prospectively enrolled participants, including endoscopic follow-up at approximately 1, 2, and 3 years after ESD and longer-term follow-up when available\n* Adequate cardiac, hepatic, renal, and pulmonary function to tolerate endoscopic treatment and routine follow-up for prospectively enrolled participants scheduled for ESD\n* Ability to provide written informed consent for prospectively enrolled participants, or availability of ethics-approved retrospective clinical data for retrospectively included participants\n\nExclusion Criteria:\n\n* Patients whose final diagnosis does not meet the study population definition, including those without early gastric cancer, high-grade intraepithelial neoplasia, or other eligible gastric neoplastic lesions\n* Insufficient clinical, H. pylori testing, endoscopic, pathological, or follow-up information to classify H. pylori infection or eradication status or to evaluate the main study outcomes\n* Lack of adequate pathological material or pathological information for assessment of gastric lesion characteristics, tissue-based H. pylori detection, or background mucosal changes\n* Previous gastrectomy or major gastric surgery that substantially alters gastric anatomy and prevents reliable assessment of lesion location, intragastric distribution, or background mucosal status\n* For prospectively enrolled participants scheduled for ESD, severe comorbid conditions, such as uncontrolled cardiovascular or cerebrovascular disease, severe coagulopathy, or very poor general condition, that make endoscopic submucosal dissection unsafe\n* For prospectively enrolled participants scheduled for ESD, anticoagulant or antiplatelet therapy that cannot be safely interrupted or managed during the perioperative period, or active bleeding tendency judged to significantly increase procedural risk\n* Pregnancy or breastfeeding for prospectively enrolled participants\n* Inability or unwillingness to comply with study procedures or follow-up requirements for prospectively enrolled participants\n* Any other condition judged by the investigators to make the participant unsuitable for the study",{"count":307,"type":22},1500,"This multicenter retrospective and prospective real-world observational study will evaluate the relationship of Helicobacter pylori (H. pylori) infection status, intragastric distribution, and pathological features with gastric cancer biological behavior and long-term prognosis in patients with early gastric cancer or related gastric neoplastic lesions undergoing endoscopic submucosal dissection (ESD).\n\nH. pylori infection is an important risk factor for gastric cancer. In clinical practice, H. pylori status can be assessed by several methods, including the 13C-urea breath test, serum H. pylori antibody testing, and pathological assessment of gastric tissue. These methods may not always provide the same result because they reflect different aspects of infection, including current active infection, previous exposure, prior eradication status, and local tissue-based detection.\n\nThe study will include approximately 1500 participants from participating medical centers. About 1000 participants will be retrospectively identified from existing clinical, endoscopic, pathological, H. pylori testing, and follow-up records, and about 500 additional participants will be prospectively enrolled.\n\nThe study will evaluate H. pylori infection status, prior eradication status, discordant testing patterns, tissue-based and intragastric H. pylori distribution, background mucosal changes, and pathological features of early gastric cancer or related gastric neoplastic lesions. These features will be analyzed in relation to different gastric cancer subtypes and biological behavior.\n\nFollow-up information will be used to evaluate whether the integrated analysis of H. pylori infection status and pathological features can predict clinical outcomes at 1, 2, and 3 years after ESD and during long-term follow-up, including local recurrence, metachronous gastric cancer, synchronous or multifocal early gastric cancer detected within 1 year, additional surgical treatment, survival, and other clinically meaningful outcomes.",[310,311],"Helicobacter Pylori","Early Gastric Cancer",[313,311,314,315,316,317,318,319,320,321,322,323,324,325,326,327,328,329],"Helicobacter pylori","Endoscopic Submucosal Dissection","ESD","13C-Urea Breath Test","Serum Helicobacter pylori Antibody","Intragastric Distribution","Gastric Cancer Pathology","H. pylori Eradication","Post-eradication Gastric Cancer","Pathological Assessment","H. pylori Test Concordance","Discordant H. pylori Testing","Background Mucosal Changes","Gastric Mucosal Atrophy","Intestinal Metaplasia","Metachronous Gastric Cancer","Long-Term Outcomes","2026-07-20",{"date":293,"type":37},{"date":333,"type":37},"2024-01-01",{"date":335,"type":22},"2031-12-30",{"name":43,"class":44},3,{"id":339,"slug":340,"hasResults":12,"nctId":341,"briefTitle":342,"officialTitle":343,"acronym":344,"eligibilityCriteria":345,"healthyVolunteers":12,"sex":17,"minAge":106,"maxAge":54,"enrollmentInfo":346,"targetDuration":4,"studyType":57,"phases":348,"briefSummary":349,"conditions":350,"keywords":352,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":356,"lastUpdatePostDateStruct":357,"startDateStruct":359,"completionDateStruct":360,"leadSponsor":362,"locationsCount":337},"100648347","phase-3-efficacy-and-safety-of-lenalidomide-in-patients-with-igg4-related-disease-100648347","NCT07719543","Efficacy and Safety of Lenalidomide in Patients With IgG4-Related Disease","A Phase III Multicenter Randomized Double-Blind Placebo-Controlled Study Evaluating the Efficacy and Safety of Lenalidomide in Patients With IgG4-Related Disease","LENITY","Inclusion Criteria:\n\n1. Adults aged 18 to 75 years at the time of screening.\n2. Diagnosis of IgG4-related disease according to the 2019 American College of Rheumatology\u002FEuropean Alliance of Associations for Rheumatology (ACR\u002FEULAR) classification criteria.\n3. Patients with IgG4-related disease who have achieved sustained clinical remission following glucocorticoid therapy.\n4. No documented IgG4-related disease relapse within the previous 12 months before screening.\n5. IgG4-related disease Responder Index (IgG4-RD RI) score of 0 at screening.\n6. Receiving stable low-dose glucocorticoid therapy with prednisone-equivalent dose ≤7.5 mg\u002Fday for at least 6 months before randomization.\n7. Ability to provide written informed consent and comply with study procedures.\n\nExclusion Criteria:\n\n1. Active IgG4-related disease requiring induction therapy or escalation of immunosuppressive treatment at screening.\n2. Previous treatment with lenalidomide or known hypersensitivity to lenalidomide or related compounds.\n3. Requirement for prohibited concomitant medications during the study period.\n4. Significant uncontrolled infection or active severe infection.\n5. Clinically significant hematologic abnormalities, including severe neutropenia or thrombocytopenia.\n6. Significant hepatic or renal dysfunction that may affect study participation or drug safety evaluation.\n7. History of thromboembolic events or conditions associated with unacceptable thrombotic risk according to investigator assessment.\n8. Pregnancy, breastfeeding, or unwillingness to use effective contraception when applicable.\n9. Malignancy or other severe medical conditions that may interfere with study participation or outcome assessment.\n10. Any condition that, in the investigator's opinion, may compromise participant safety or affect the reliability of study results.",{"count":347,"type":22},146,[59],"Immunoglobulin G4-related disease (IgG4-RD) is a chronic immune-mediated disorder characterized by inflammation, fibrosis, and involvement of multiple organs. Although glucocorticoids can effectively induce remission, many patients experience disease relapse after glucocorticoid tapering or discontinuation, and long-term glucocorticoid exposure may cause significant adverse effects. Therefore, new maintenance treatment strategies are needed to reduce relapse risk and minimize glucocorticoid-related toxicity.\n\nThis study is designed to evaluate the efficacy and safety of lenalidomide as a maintenance therapy in patients with stable IgG4-RD. This is a multicenter, randomized, double-blind, placebo-controlled phase III clinical trial.\n\nEligible participants will be adults with IgG4-RD who meet the 2019 ACR\u002FEULAR IgG4-RD classification criteria and are in a stable disease state. Participants will be randomly assigned in a 1:1 ratio to receive either lenalidomide or matching placebo for 52 weeks. All participants will receive standardized glucocorticoid tapering according to the study protocol.\n\nThe primary objective of this study is to determine whether lenalidomide can reduce the risk of IgG4-RD relapse compared with placebo. The primary outcome is the proportion of participants experiencing disease relapse within 52 weeks after randomization.\n\nSecondary objectives include evaluation of time to relapse, maintenance of remission, changes in disease activity, quality of life, and safety outcomes. Exploratory assessments will investigate changes in immunological biomarkers, peripheral blood immune profiles, transcriptomic characteristics, and gut microbiota.\n\nThis study aims to provide clinical evidence for a new maintenance treatment approach for patients with IgG4-RD and potentially reduce disease recurrence and glucocorticoid exposure.",[351],"Immunoglobulin G4-Related Disease",[353,354,355],"IgG4-related disease","Lenalidomide","Maintenance therapy","2026-07-18",{"date":358,"type":37},"2026-07-22",{"date":95,"type":22},{"date":361,"type":22},"2030-12-31",{"name":43,"class":44},{"id":364,"slug":365,"hasResults":12,"nctId":366,"briefTitle":367,"officialTitle":368,"acronym":369,"eligibilityCriteria":370,"healthyVolunteers":12,"sex":185,"minAge":371,"maxAge":137,"enrollmentInfo":372,"targetDuration":4,"studyType":57,"phases":374,"briefSummary":375,"conditions":376,"keywords":380,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":356,"lastUpdatePostDateStruct":386,"startDateStruct":387,"completionDateStruct":389,"leadSponsor":391,"locationsCount":45},"100636760","thulium-laser-enucleation-with-bladder-neck-incision-for-small-volume-benign-prostatic-hyperplasia-100636760","NCT07569874","Thulium Laser Enucleation With Bladder Neck Incision for Small-Volume Benign Prostatic Hyperplasia","Thulium Laser Enucleation of the Prostate Combined With Bladder Neck Incision for Small-Volume Benign Prostatic Hyperplasia: A Multicentre, Randomized, Single-Blind, Four-Arm Controlled Trial","ThuLEP-BNI","Inclusion Criteria:\n\n* Male patients aged 40-80 years.\n* Diagnosis of benign prostatic hyperplasia (BPH) and scheduled to undergo surgical treatment.\n* International Prostate Symptom Score (IPSS) of at least 12, maximum urinary flow rate of no more than 15 mL\u002Fs, with a voided volume greater than 150 mL.\n* Prostate volume of less than 30 mL measured by transrectal ultrasound (TRUS), calculated as length × width × height × 0.52.\n* Ability, as assessed by the investigator, to understand the study requirements and complete the scheduled treatment, follow-up visits, and study-related assessments.\n\nExclusion Criteria:\n\n* Inability or refusal to provide written informed consent, or inability to comply with the required follow-up schedule.\n* Prostate-specific antigen (PSA) level of 10 ng\u002FmL or higher, unless prostate cancer has been excluded by biopsy.\n* Confirmed or suspected prostate or bladder malignancy.\n* Pre-existing bladder neck contracture or urethral stricture before surgery.\n* Known coagulation disorder or abnormal coagulation function.\n* Neurogenic bladder or detrusor underactivity that may affect bladder or urethral sphincter function.\n* Benign prostatic hyperplasia (BPH) complicated by acute urinary tract infection, acute prostatitis, or bacterial prostatitis.\n* History of prostate surgery, urethral stricture, or neurogenic bladder.\n* History of prostate cancer or pelvic radiotherapy.\n* Severe cardiovascular disease, pulmonary disease, or other systemic disease that, in the investigator's judgment, would make the patient unable to tolerate surgery.\n* Participation in another clinical trial related to benign prostatic hyperplasia (BPH) within 3 months before enrolment.\n* Any other condition that, in the investigator's opinion, makes the patient unsuitable for participation in this study.","40 Years",{"count":373,"type":22},932,[86],"This study will evaluate the safety and effectiveness of different surgical treatments for men with small-volume benign prostatic hyperplasia (BPH). Men with small-volume BPH may still have bothersome lower urinary tract symptoms and bladder outlet obstruction, and the best surgical treatment for this group remains uncertain.\n\nIn this multicentre, randomized, single-blind, four-arm controlled trial, 932 eligible men aged 40 to 80 years will be assigned in a 1:1:1:1 ratio to one of four groups: thulium laser enucleation of the prostate combined with bladder neck incision, thulium laser enucleation of the prostate alone, transurethral resection of the prostate (TURP), or transurethral incision of the prostate (TUIP).\n\nThe main goal of the study is to compare the incidence of bladder neck contracture at 6 months after surgery. Secondary outcomes include safety outcomes and changes in urinary symptoms, urinary flow rate, pain score, and symptom response at 3 and 6 months after surgery. Exploratory outcomes include changes in post-void residual urine volume and sexual function scores. Additional exploratory long-term outcomes will also be assessed at 12 months after surgery.",[377,378,379],"Benign Prostatic Hyperplasia","Bladder Outlet Obstruction","Lower Urinary Tract Symptoms (LUTS)",[381,382,383,384,385],"Small-Volume Benign Prostatic Hyperplasia","Thulium Laser Enucleation of the Prostate","Bladder Neck Incision","Bladder Neck Contracture","Lower Urinary Tract Symptoms",{"date":291,"type":37},{"date":388,"type":22},"2026-07",{"date":390,"type":22},"2028-12",{"name":43,"class":44},{"id":393,"slug":394,"hasResults":12,"nctId":395,"briefTitle":396,"officialTitle":397,"acronym":4,"eligibilityCriteria":398,"healthyVolunteers":12,"sex":17,"minAge":106,"maxAge":54,"enrollmentInfo":399,"targetDuration":4,"studyType":57,"phases":401,"briefSummary":402,"conditions":403,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":405,"lastUpdatePostDateStruct":406,"startDateStruct":407,"completionDateStruct":408,"leadSponsor":409,"locationsCount":45},"100637916","phase-1-safety-and-efficacy-of-ksvcbd-injection-in-b-cell-non-hodgkins-lymphoma-expressing-cd19-andor-bcma-100637916","NCT07620314","Safety and Efficacy of KSVCBD Injection in B-cell Non-Hodgkin's Lymphoma Expressing CD19 and\u002For BCMA","A Clinical Study on the Safety and Efficacy of KSVCBD Injection in the Treatment of B-cell Non-Hodgkin's Lymphoma With Positive Expression of CD19 and\u002For BCMA","Key Inclusion Criteria:\n\n1. Age 18-75 years (inclusive), any gender.\n2. Subjects must meet the following diagnostic and treatment criteria:\n\n   2.1Histologically or cytologically confirmed B-NHL (according to the 2016 WHO classification of lymphoid neoplasms):\n   * Diffuse large B-cell lymphoma, not otherwise specified.\n   * Primary mediastinal large B-cell lymphoma.\n   * Diffuse large B-cell lymphoma transformed from follicular lymphoma (TFL).\n   * High-grade B-cell lymphoma with MYC and BCL2 and\u002For BCL6 rearrangements.\n   * Follicular lymphoma (FL).\n   * High-grade B-cell lymphoma, not otherwise specified.\n   * Mantle cell lymphoma (pathologically confirmed, with monoclonal B cells carrying t(11.14) and\u002For overexpressing cyclin D1).\n   * Marginal zone lymphoma (including nodal or splenic marginal zone B-cell lymphoma and mucosa-associated lymphoid tissue \\[MALT\\] lymphoma).\n\n   2.2Subjects must be in a relapsed or refractory state during the screening period:\n   * Definition of relapse: Disease progression (PD) after achieving remission (including PR or CR) following at least one standard treatment regimen (must include rituximab and anthracyclines).\n   * Definition of refractory: Must meet any of the following criteria:\n\n   Best response of stable disease (SD) or PD after at least 4 cycles of first-line standard treatment (e.g., 4 cycles of R-CHOP).\n\n   Achieved remission after at least 6 cycles of first-line standard treatment but experienced PD within 6 months.\n\n   Best response of PD after first-line standard treatment. Relapse (must be biopsy-proven) or PD within 12 months after autologous stem cell transplantation (ASCT). if salvage therapy was received, no response (SD or PD) to the last line of treatment.\n   * For TFL, subjects must have received adequate prior treatment for follicular lymphoma, at least one line of treatment for TFL after transformation, and be relapsed or refractory after the last line of treatment.\n   * For mantle cell lymphoma, prior treatment must include anthracycline- or bendamustine-containing chemotherapy, anti-CD20 therapy (except for CD20-negative cases), and BTK inhibitor therapy.\n   * For indolent lymphomas (grade 1-3a FL and marginal zone lymphoma), subjects must have received at least two prior lines of therapy.\n   * For other types, prior treatment must include anti-CD20 therapy (except for CD20-negative cases) and anthracycline-containing chemotherapy.\n\n   2.3Subjects judged by the investigator to be intolerant to standard therapy may also be included in the study.\n3. Intranodal lesion with long-axis diameter \\> 1.5 cm, or extranodal lesion with long-axis diameter \\> 1.0 cm (according to the 2014 Lugano response criteria).\n4. Positive expression of CD19 and\u002For BCMA in tumor tissue confirmed by flow cytometry and\u002For histopathology (previous pathology or flow cytometry diagnosis of CD19 and\u002For BCMA in the patient, as confirmed by the investigator, is acceptable). For subjects who have previously received anti-CD19 and\u002For anti-BCMA therapy, a tumor biopsy should be performed to confirm current positive expression of CD19 and\u002For BCMA.\n5. Toxicities from any prior therapy must be stable and have resolved to ≤ Grade 1 (excluding hematologic toxicities and clinically insignificant toxicities such as alopecia).\n6. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2.\n\nKey Exclusion Criteria:\n\n1. Expected survival \\\u003C 3 months.\n2. History of or concurrent active malignancy. Exceptions include: carcinoma in situ of the cervix that has been cured or with no recurrence for at least 3 years, non-invasive basal cell or squamous cell skin cancer, locally advanced prostate cancer that has received curative treatment, or ductal carcinoma in situ after radical surgery.\n3. Prior allogeneic hematopoietic stem cell transplantation (allo-HSCT) or autologous HSCT within 3 months prior to KSVCBD infusion.\n4. Solitary extramedullary soft tissue plasmacytoma.\n5. Diagnosis of plasma cell leukemia, Waldenström's macroglobulinemia, POEMS syndrome, or primary AL amyloidosis.\n6. Presence of CNS metastasis or symptoms of CNS metastasis.\n7. Receipt of anti-tumor therapy that is still within 5 half-lives prior to the planned KSVCBD infusion.\n8. Presence of uncontrolled active infections.\n9. Positive for human immunodeficiency virus (HIV) antibody, positive for Treponema pallidum antibody, positive for hepatitis B surface antigen (HBsAg) or positive for hepatitis B core antibody (HBcAb) with detectable peripheral blood HBV DNA, or positive for hepatitis C virus (HCV) antibody with detectable HCV RNA. except for infections that the investigator judges can be prevented or controlled with medication.\n10. Known active autoimmune disease requiring systemic treatment.\n11. Known severe allergy to the study drug or any of its components.\n12. Pregnant or breastfeeding women.\n13. Receipt of a live vaccine within 6 weeks prior to enrollment.",{"count":400,"type":22},9,[110],"KSVCBD injection is an in vivo Chimeric Antigen Receptor T-Cell (CAR-T cell) therapy product. This multicenter, single-arm, open-label, early exploratory clinical study is designed to evaluate the preliminary safety and efficacy of KSVCBD injection in patients with relapsed or refractory (r\u002Fr) B-cell non-Hodgkin's lymphoma (NHL) CD19 and\u002For BCMA.",[404],"Non-Hodgkin's Lymphoma","2026-07-16",{"date":330,"type":37},{"date":405,"type":37},{"date":269,"type":22},{"name":43,"class":44},{"id":411,"slug":412,"hasResults":12,"nctId":413,"briefTitle":414,"officialTitle":415,"acronym":4,"eligibilityCriteria":416,"healthyVolunteers":12,"sex":17,"minAge":106,"maxAge":4,"enrollmentInfo":417,"targetDuration":4,"studyType":57,"phases":418,"briefSummary":419,"conditions":420,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":405,"lastUpdatePostDateStruct":427,"startDateStruct":428,"completionDateStruct":430,"leadSponsor":432,"locationsCount":45},"100552334","phase-2-combination-of-zanubrutinib-rituximab-and-venetoclax-in-patients-with-previously-untreated-follicular-lymphoma-100552334","NCT06471738","Combination of Zanubrutinib, Rituximab and Venetoclax in Patients With Previously Untreated Follicular Lymphoma","Safety and Efficacy of Zanubrutinib in Combination With Rituximab and Venetoclax in Previously Untreated Follicular Lymphoma: An Open Label, Phase 2 Study","Inclusion Criteria:\n\n* A diagnosis of follicular lymphoma (grades 1, 2, or 3a), untreated.\n* Stage II, III, or IV disease.\n* Able and willing to provide written informed consent and to comply with the study protocol.\n* at least one measurable disease.\n* Must be in need of therapy as evidenced by at least one of the following criteria:\n\n  * Presence of at least one B symptom: Fever (\\> 38 Celsius \\[C\\]) not due to infectious etiology, or Night sweats, or Weight loss \\> 10% in the past 6 months;\n  * Fatigue due to lymphoma;\n  * Splenomegaly (\\> 13 cm);\n  * Compression syndrome (ureteral, orbital, gastrointestinal);\n  * Any of the following cytopenias, due to lymphoma: Hemoglobin ≤ 10 g\u002FdL, or Platelets ≤ 100 x 10\\^9\u002FL, or Absolute neutrophil count (ANC) \\\u003C 1.5 x 10\\^9\u002FL;\n  * Pleural or peritoneal effusion;\n  * Lactate dehydrogenase (LDH) \\> upper limit of normal (ULN) or beta (B)2 microglobulin \\> ULN;\n  * Other lymphoma-mediated symptoms as determined by the treating physician.\n* ECOG ≤ 2\n* ANC \\> 1.0 x 10\\^9\u002FL (for patients without bone marrow involvement by lymphoma)\n* Platelet count \\> 50 x 10\\^9\u002FL (for patients without bone marrow involvement by lymphoma)\n* Prothrombin time (PT)\u002Finternational normal ratio (INR) \\\u003C 1.5 x (upper limit of normal) ULN and partial thromboplastin time (PTT) (activated partial thromboplastin time \\[aPTT\\]) \\\u003C 1.5 x ULN (unless abnormalities are unrelated to coagulopathy or bleeding disorder). When treated with warfarin or other vitamin K antagonists, then INR ≤ 3.0)\n* Serum aspartate transaminase (AST) and alanine transaminase (ALT) \\\u003C 3 x ULN\n* Creatinine clearance \\> 30 ml\u002Fmin calculated by modified Cockcroft-Gault formula\n* Bilirubin \\\u003C 1.5 x ULN unless bilirubin is due to Gilbert's syndrome, documented liver involvement with lymphoma, or of non-hepatic origin, in which case bilirubin should not exceed 3 g\u002FdL\n* Women of childbearing potential must have a negative serum (beta-human chorionic gonadotropin \\[B-hCG\\]) pregnancy test at screening. Women who are pregnant or breastfeeding are ineligible for this study\n\nExclusion Criteria:\n\n* Known active central nervous system lymphoma or leptomeningeal disease\n* Follicular lymphoma with evidence of diffuse large B-cell transformation\n* Grade 3b follicular lymphoma\n* Any prior history of other malignancy besides follicular lymphoma\n* History of severe allergic or anaphylactic reactions to monoclonal antibody therapy\n* Patients who have undergone major surgery within 14 days\n* The researchers believe that it is not advisable for the participant to take part in this trial.",{"count":189,"type":22},[256],"This is a single center, open label, single arm phase II clinical trial. The objective of this study is to assess the feasibility and efficacy of zanubrutinib combined with venetoclax and Rituximab in patients with previously untreated follicular lymphoma (FL) .",[421,422,423,424,425,426],"Ann Arbor Stage II Follicular Lymphoma","Grade 1 Follicular Lymphoma","Ann Arbor Stage III Follicular Lymphoma","Ann Arbor Stage IV Follicular Lymphoma","Grade 2 Follicular Lymphoma","Grade 3a Follicular Lymphoma",{"date":330,"type":37},{"date":429,"type":37},"2024-07-10",{"date":431,"type":22},"2027-06-01",{"name":43,"class":44},{"id":434,"slug":435,"hasResults":12,"nctId":436,"briefTitle":437,"officialTitle":438,"acronym":439,"eligibilityCriteria":440,"healthyVolunteers":12,"sex":17,"minAge":106,"maxAge":137,"enrollmentInfo":441,"targetDuration":4,"studyType":57,"phases":442,"briefSummary":443,"conditions":444,"keywords":446,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":449,"lastUpdatePostDateStruct":450,"startDateStruct":452,"completionDateStruct":454,"leadSponsor":456,"locationsCount":457},"100590622","phase-2-safety-and-efficacy-of-mesenchymal-stromal-cells-amimestrocel--in-diabetic-kidney-disease-100590622","NCT06969807","Safety and Efficacy of Mesenchymal Stromal Cells (Amimestrocel ) in Diabetic Kidney Disease","Clinical Study to Evaluate the Efficacy and Safety of Mesenchymal Stromal Cell (Amimestrocel ) in Patients With Diabetic Kidney Disease","MSC-DKD-001","Inclusion Criteria: -\n\n1. Men and women who are ≥18 and ≤ 80 years old.\n2. Diagnosed with type 2 diabetes mellitus.\n3. Diagnosed with diabetic kidney disease based on renal pathology within the past 10 years.\n4. The 24-hour urine protein quantification is continuously ≥ 3.5 g, or the urine albumin-to-creatinine ratio (UACR) \\> 1000 mg\u002Fg.\n5. The estimated glomerular filtration rate (eGFR) ≥ 15 ml\u002Fmin\u002F1.73m² (calculated according to the CKD-EPI formula).\n6. The blood pressure can be controlled at BP ≤ 160\u002F100 mmHg.\n7. Glycated hemoglobin (HbA1c) \\\u003C 9%.\n8. Willing and able to provide written informed consent.\n\nExclusion Criteria:\n\n1. Patients with kidney diseases not caused by diabetes mellitus.\n2. Patients who have received treatment with systemic immunosuppressants (such as cyclosporine A, tacrolimus, mycophenolate mofetil, etc.) within 30 days before enrollment and the duration of treatment exceeds one week.\n3. Severe cardiovascular diseases, such as congenital heart diseases, atrial fibrillation, NYHA class Ⅲ-IV, unstable angina pectoris, etc.\n4. A history of cerebral hemorrhage or cerebral infarction within the past six months (except for those with a history of lacunar cerebral infarction without residual limb movement disorders, cognitive and language function disorders).\n5. Patients with severe hyperlipidemia: (serum triglyceride ≥ 6.2 mmol\u002FL, serum low-density lipoprotein cholesterol ≥ 4.1 mmol\u002FL).\n6. Hyperkalemia that cannot be controlled through diet or potassium-lowering treatment.\n7. Patients with active infections of hepatitis B or hepatitis C viruses (the copy number of HBV DNA or HCV RNA exceeds the upper limit of the normal value); patients with active tuberculosis; patients with severe immunodeficiency diseases, human immunodeficiency virus (HIV) infection, etc.\n8. Patients with a history of malignant tumors within the past five years.\n9. Patients with a known history of severe allergy to component blood or blood products, or patients with a history of allergy to heterologous proteins.\n10. Lactating women, or female patients who have a pregnancy plan or an egg donation plan from the start of the study to the follow-up period, and male patients (or their partners) who have a childbearing plan or a sperm donation plan from the start of the study to the follow-up period and are unwilling to take contraceptive measures.\n11. Active infection within one week before enrollment and requiring treatment with intravenous antibiotics.\n12. Patients who have participated in other interventional clinical trials within three months before enrollment.\n13. The research physician deems that the patient's condition is not suitable for participating in this clinical study.",{"count":56,"type":22},[256],"This trial is to evaluate the efficacy and safety of umbilical cord-derived mesenchymal stromal cells (Amimestrocel ) in study subjects with progressive diabetic kidney disease (DKD), to investigate whether Amimestrocel can improve renal function or proteinuria of DKD patients.",[445],"Diabetic Kidney Disease (DKD)",[447,448],"mesenchymal stromal cells(MSCs)","Diabetic kidney disease (DKD)","2026-07-12",{"date":451,"type":37},"2026-07-14",{"date":453,"type":37},"2025-06-09",{"date":455,"type":22},"2028-05-15",{"name":43,"class":44},6,{"id":459,"slug":460,"hasResults":12,"nctId":461,"briefTitle":462,"officialTitle":462,"acronym":463,"eligibilityCriteria":464,"healthyVolunteers":12,"sex":17,"minAge":106,"maxAge":54,"enrollmentInfo":465,"targetDuration":4,"studyType":57,"phases":467,"briefSummary":468,"conditions":469,"keywords":471,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":449,"lastUpdatePostDateStruct":474,"startDateStruct":475,"completionDateStruct":477,"leadSponsor":478,"locationsCount":457},"100589463","phase-2-clinical-study-to-evaluate-the-efficacy-and-safety-of-mesenchymal-stromal-cells-amimestrocel--in-patients-with-acute-kidney-injury-100589463","NCT06954740","Clinical Study to Evaluate the Efficacy and Safety of Mesenchymal Stromal Cells (Amimestrocel ) in Patients With Acute Kidney Injury","MSC-AKI-001","Inclusion Criteria:\n\n1. Aged between 18 and 75 years old; gender is not restricted.\n2. According to the 2023 KDIGO diagnostic criteria for acute kidney injury (AKI), including those that occur during the course of the disease in various patients with chronic kidney disease (CKD), AKI can be diagnosed if any of the following conditions is met:\n\n   ① The serum creatinine level increases by ≥ 26.5 μmol\u002FL within 48 hours;\n\n   ② The serum creatinine level increases by more than 1.5 times or higher than the baseline value within 7 days;\n\n   ③ The urine output decreases (\\\u003C 0.5 mL\u002Fkg\u002Fh) and persists for more than 6 hours; The baseline value of serum creatinine: The lowest creatinine value obtained in the outpatient department or ward within 3 months, and the longest time limit is the creatinine value within 1 year. If there is no such value, the serum creatinine can be estimated using the MDRD equation under the assumption that the baseline eGFR is 75 ml\u002Fmin\u002F1.73m².\n3. .Ability to give informed consent.\n\nExclusion Criteria:\n\n1. Post-renal AKI.\n2. Acute kidney injury caused by glomerular diseases such as rapidly progressive glomerulonephritis, lupus nephritis, anti-neutrophil cytoplasmic antibody-associated nephritis, anti-glomerular basement membrane antibody-mediated nephritis, vasculitis, cryoglobulinemia, thrombotic microangiopathy, etc.\n3. Hemodynamic instability.\n4. Severe cardiovascular diseases.\n5. Severe pulmonary dysfunction.\n6. A history of intracerebral hemorrhage or cerebral infarction within the past six months.\n7. Subjects with abnormal laboratory indicators: AST or ALT \\> 5 × upper limit of normal value (ULN); total bilirubin \\> 3 × ULN; white blood cell count \\\u003C 2000\u002FμL (2 × 10⁹\u002FL), hemoglobin \\\u003C 6 g\u002FdL (60 g\u002FL), neutrophils \\\u003C 1000\u002FμL (1 × 10⁹\u002FL), platelets \\\u003C 50000\u002FμL (50 × 10⁹\u002FL).\n8. Uncontrollable infection.\n9. Patients with active hepatitis B or hepatitis C virus infection, active tuberculosis, severe immunodeficiency diseases, human immunodeficiency virus (HIV) infection, etc.\n10. Received systemic immunosuppressants or glucocorticoid treatment for more than one week within 30 days before enrollment.\n11. Have received hemodialysis or peritoneal dialysis treatment.\n12. Have a history of hematopoietic stem cell transplantation or solid organ transplantation.\n13. Patients with a history of malignant tumor within the past 5 years.\n14. Life expectancy is less than 1 month.\n15. Those with a known history of severe allergy to component blood or blood products, or those with a history of allergy to heterologous proteins.\n16. Lactating women, or female patients who have a pregnancy plan or an egg donation plan from the start of the study to the follow-up period, and male patients (or their partners) who have a fertility plan or a sperm donation plan from the start of the study to the follow-up period and are unwilling to take contraceptive measures.\n17. Patients who participated in other interventional clinical trials within 1 month before enrollment.",{"count":466,"type":22},50,[256],"This trial is to evaluate the efficacy and safety of Amimestrocel (human umbilical cord mesenchymal stromal cells) in the treatment of AKI patients.",[470],"Acute Kidney Injury",[472,473],"mesenchymal stromal cells (MSCs)","acute kidney injury(AKI)",{"date":451,"type":37},{"date":476,"type":37},"2025-06-10",{"date":455,"type":22},{"name":43,"class":44},{"id":480,"slug":481,"hasResults":12,"nctId":482,"briefTitle":483,"officialTitle":484,"acronym":4,"eligibilityCriteria":485,"healthyVolunteers":12,"sex":17,"minAge":106,"maxAge":4,"enrollmentInfo":486,"targetDuration":4,"studyType":57,"phases":487,"briefSummary":489,"conditions":490,"keywords":492,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":499,"lastUpdatePostDateStruct":500,"startDateStruct":502,"completionDateStruct":503,"leadSponsor":505,"locationsCount":45},"100644618","early-phase-1-gofast-car-t-cell-therapy-for-recurrent-refractory-b-cell-lymphoma-100644618","NCT07670260","GoFast CAR T-Cell Therapy for Recurrent Refractory B-Cell Lymphoma","Exploratory Clinical Study of GoFast CAR T-Cell Platform Targeting CD19 CAR T-Cell Therapy for Recurrent Refractory B-Cell Lymphoma","Inclusion Criteria:\n\n* Age 18 years or older.\n* Histologically or cytologically confirmed primary refractory or relapsed\u002Fprogressive large B-cell lymphoma.\n* Expected survival of more than 3 months.\n* CD19-positive B-cell lymphoma confirmed by flow cytometry or immunohistochemistry.\n* ECOG performance status of 0 to 2 or KPS score greater than 80.\n* Adequate venous access for leukapheresis or peripheral blood collection, with no contraindication to blood cell separation.\n* White blood cell count ≥ 1 × 10\\^9\u002FL and lymphocyte count ≥ 0.3 × 10\\^9\u002FL.\n* INR \\\u003C 1.7 or prothrombin time prolonged by less than 4 seconds above the normal value.\n* ALT and AST ≤ 2.5 × upper limit of normal.\n* Total bilirubin ≤ 2.0 mg\u002FdL, equivalent to 34.2 μmol\u002FL.\n* Able to understand and voluntarily sign the written informed consent form.\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding women.\n* Active hepatitis B virus or hepatitis C virus infection.\n* HIV\u002FAIDS infection.\n* Any uncontrolled active infection.\n* Systemic corticosteroid use within 2 weeks before signing informed consent, except inhaled corticosteroids.\n* Active cardiac disease requiring treatment or poorly controlled hypertension.\n* Unstable or active ulcer disease or gastrointestinal bleeding.\n* History of organ transplantation or currently awaiting organ transplantation.\n* Central nervous system involvement by lymphoma.\n* Current participation in another clinical trial.\n* Any other condition that, in the investigator's judgment, makes the participant unsuitable for this clinical study.",{"count":400,"type":22},[488],"EARLY_PHASE1","This is an investigator-initiated, prospective, open-label exploratory clinical study designed to evaluate the safety and preliminary efficacy of GoFast CD19 CAR T-cell therapy in adult patients with recurrent or refractory B-cell lymphoma. Eligible patients will undergo screening, baseline assessment, peripheral blood or leukapheresis collection, lymphodepleting chemotherapy, and intravenous infusion of GoFast CD19 CAR T cells. The study plans to enroll 9 participants using a sequential dose-escalation design. The primary outcome is objective response rate, and secondary outcomes include complete remission rate, overall survival, progression-related survival outcomes, duration of response, MRD negativity, and adverse events.",[491],"Relapsed or Refractory Large B-cell Lymphoma",[116,493,494,495,496,497,498],"CAR T-Cell Therapy","GoFast Platform","Large B-Cell Lymphoma","Relapsed or Refractory Lymphoma","Dose Escalation","Autologous CAR T Cells","2026-06-25",{"date":501,"type":37},"2026-06-26",{"date":153,"type":22},{"date":504,"type":22},"2028-06-30",{"name":43,"class":44},{"id":507,"slug":508,"hasResults":12,"nctId":509,"briefTitle":510,"officialTitle":511,"acronym":4,"eligibilityCriteria":512,"healthyVolunteers":12,"sex":17,"minAge":106,"maxAge":54,"enrollmentInfo":513,"targetDuration":4,"studyType":57,"phases":514,"briefSummary":515,"conditions":516,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":518,"lastUpdatePostDateStruct":519,"startDateStruct":521,"completionDateStruct":523,"leadSponsor":525,"locationsCount":337},"100642359","early-phase-1-the-safety-and-efficacy-of-allogeneic-cd70-car-t-therapy-in-unresectable-or-metastatic-clear-cell-renal-cell-carcinoma-100642359","NCT07645690","The Safety and Efficacy of Allogeneic CD70 CAR-T Therapy in Unresectable or Metastatic Clear Cell Renal Cell Carcinoma","A Clinical Study to Evaluate the Safety and Efficacy of Allogeneic CD70 CAR-T Therapy in Patients With Unresectable or Metastatic Clear Cell Renal Cell Carcinoma","Key Inclusion Criteria:\n\n1.Age 18-75 years (inclusive), any gender. 2.Confirmed by histopathology and\u002For cytology as unresectable or metastatic clear cell renal cell carcinoma; 3.Local progression or metastasis after receiving at least second line therapy \\[including at least one immune checkpoint inhibitor (ICI) and at least one vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI)\\]; 4.Willing to undergo tumor tissue sample collection or provide previous tumor tissue samples for CD70 expression level testing; 5.Positive CD70 expression by immunohistochemical (IHC) staining of tumor tissue (percentage of positive cells ≥ 10%); 6.At least one measurable lesion according to RECIST v1.1 criteria. 7.Karnofsky Performance Status (KPS) ≥ 70%. 8.Organ function must meet the following criteria:\n\n1. Complete blood count (no G-CSF within 1 week prior to blood count testing. or no pegylated G-CSF within 2 weeks prior to blood count testing): Absolute neutrophil count (ANC) ≥ 1.0×10⁹\u002FL. platelet count (PLT) ≥ 100×10⁹\u002FL. hemoglobin ≥ 80 g\u002FL (excluding bone marrow suppression caused by lymphoma involvement of the bone marrow).\n2. Coagulation function: International normalized ratio (INR) ≤ 1.5×ULN, and activated partial thromboplastin time (APTT) ≤ 1.5×ULN.\n3. Liver function: Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3×ULN (if with liver metastasis, AST and ALT ≤ 5×ULN). total bilirubin ≤ 1.5×ULN.\n4. Renal function: Serum creatinine ≤ 1.5×ULN or creatinine clearance (Cockcroft-Gault formula) ≥ 60 mL\u002Fmin.\n5. Cardiac function: Left ventricular ejection fraction (LVEF) on echocardiography (ECHO) ≥ 50%, no pericardial effusion. no clinically significant abnormalities on 12-lead electrocardiogram (ECG).\n6. Pulmonary function: End-blood oxygen saturation ≥ 92% while breathing room air without supplemental oxygen. no clinically significant pleural effusion.\n\n9.Subjects and\u002For their partners of childbearing potential agree to use effective contraceptive measures throughout the entire treatment period and for 52 weeks after treatment, and during this period they must not donate eggs\u002Fsperm for assisted reproduction; Female participants of childbearing potential (women who have undergone sterilization surgery or have been postmenopausal for ≥12 months are not considered to have childbearing potential) must present a negative pregnancy test at screening and agree to use effective contraception throughout the study period.\n\n10.Willing to comply with all study procedures and voluntarily participate in this study and sign the informed consent form (ICF).\n\nKey Exclusion Criteria:\n\n1. Expected survival \\\u003C 3 months.\n2. Prior or concurrent active malignancy, with the exception of cured or recurrence-free for at least 3 years of cervical carcinoma in situ, non-invasive basal cell or squamous cell skin cancer, or locally advanced prostate cancer that has received curative treatment, or ductal carcinoma in situ after radical surgery.\n3. Prior use of CD70-targeted therapy.\n4. Previous treatment with CAR-T or any other genetically engineered cell therapy.\n5. History of central nervous system (CNS) disease or clinically significant CNS dysfunction, such as cerebral ischemia\u002Fhemorrhage, dementia, cerebellar disease, epilepsy, aphasia, dementia, etc.\n6. History of major organ transplantation (e.g., heart, lung, kidney, liver) or hematopoietic stem cell\u002Fbone marrow transplantation.\n7. Occurrence of myocardial infarction, cardiac angioplasty or stent implantation, unstable angina, or other clinically significant cardiac diseases within 12 months prior to screening.\n8. Presence of CNS metastasis or symptoms of CNS metastasis.\n9. Toxicities from prior therapy have not recovered to CTCAE grade ≤ 1, except for adverse events without safety risks (e.g., alopecia).\n10. The anti-tumor therapy received is still within 5 half-lives prior to the planned ET-970 infusion.\n11. Presence of uncontrolled active bacterial, fungal, or viral infections, or other infections deemed by the investigator as unsuitable for study participation.\n12. Positive for human immunodeficiency virus (HIV) antibody, positive for Treponema pallidum antibody, positive for hepatitis B surface antigen (HBsAg) or positive for hepatitis B core antibody (HBcAb) with detectable peripheral blood HBV DNA, positive for hepatitis C virus (HCV) antibody with detectable HCV RNA; except for infections that can be prevented or controlled with medication as judged by the investigator.\n13. History of other autoimmune diseases requiring immunosuppressive therapy.\n14. Known severe allergy to the study drug or any of its components.\n15. Pregnant or breastfeeding women.\n16. Use of any live vaccines against infectious disease within 6 weeks before lymphodepletion conditioning.\n17. Participation in another interventional clinical study and receipt of an active investigational drug within 3 months prior to signing the ICF, or intention to participate in another clinical trial or receive treatment for autoimmune diseases outside the protocol during the entire study period.\n18. Psychiatric disorders with depression or suicidal tendencies.\n19. Presence of any other medical condition that may affect the evaluation of the safety and efficacy of the study drug.\n20. Other factors due to which the patient is deemed unsuitable for participation by the investigator.",{"count":189,"type":22},[488],"CLEAR CAR-T cell injection (ET-970) is an engineered CD70-targeting allogeneic Chimeric Antigen Receptor T-Cell (CAR-T cell). This is a multi-center, single-arm, open-label, early exploratory clinical study. The objective of this study is to evaluate the safety and preliminary efficacy of ET-970 in unresectable or metastatic clear cell renal cell carcinoma.",[517],"Unresectable or Metastatic Clear Cell Renal Cell Carcinoma","2026-06-17",{"date":520,"type":37},"2026-06-22",{"date":522,"type":22},"2026-07-01",{"date":524,"type":22},"2028-03-31",{"name":43,"class":44},{"id":527,"slug":528,"hasResults":12,"nctId":529,"briefTitle":530,"officialTitle":530,"acronym":4,"eligibilityCriteria":531,"healthyVolunteers":12,"sex":17,"minAge":106,"maxAge":137,"enrollmentInfo":532,"targetDuration":4,"studyType":57,"phases":534,"briefSummary":535,"conditions":536,"keywords":4,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":538,"lastUpdatePostDateStruct":539,"startDateStruct":541,"completionDateStruct":542,"leadSponsor":544,"locationsCount":45},"100642235","clinical-study-on-the-efficacy-and-safety-of-nalfurafine-hydrochloride-orally-disintegrating-tablets-in-treating-pruritus-in-patients-undergoing-maintenance-hemodialysis-100642235","NCT07650851","Clinical Study on the Efficacy and Safety of Nalfurafine Hydrochloride Orally Disintegrating Tablets in Treating Pruritus in Patients Undergoing Maintenance Hemodialysis","Inclusion Criteria:\n\n* Age range of 18-80 years old (including both ends), male or female not limited.\n* Chronic renal failure patients who undergo stable dialysis for 3 months or more, receive regular hemodialysis 3 times a week, and are expected to have no significant changes in treatment or rapid changes in their condition during the clinical trial period.\n* Within one year prior to signing the informed consent form, the effectiveness of itch treatment (including topical medications such as moisturizers\u002Fmoisturizers, systemic medications such as antihistamines or antiepileptic drugs, and non pharmacological treatments) was not satisfactory.\n* Those who are able to understand and comply with the research procedures and methods, voluntarily participate in this study, and sign a written informed consent form.\n* The number of days during which VAS values are measured at both wake-up and bedtime in the baseline period must be no less than 5 days, and the average value of the larger VAS values in morning and evening measurements must not be less than 50 mm.\n* The number of days evaluated for the severity of itching in Xie Chuandao during the baseline period must be no less than 5 days at both wake-up and bedtime.\n\nExclusion Criteria:\n\n* Given poor compliance with dialysis treatment, researchers believe that it may affect the effectiveness and safety of clinical studies.\n* Patients who plan to undergo kidney transplantation or other elective surgeries during the study period.\n* Patients with alanine aminotransferase (ALT), aspartate aminotransferase (AST), or glutamine transferase (GGT) levels exceeding the upper limit of normal (ULN) by 2 times, or total bilirubin levels exceeding the upper limit of normal (ULN) by 2 times during the screening period.\n* Skin itching is not caused by chronic kidney disease, including allergic skin diseases (atopic dermatitis, urticaria, eczema, drug rash, etc.), physical skin diseases (prickly heat, solar rash, etc.), infectious skin diseases (insect bite dermatitis, chickenpox, measles, pyoderma, tinea corporis, etc.), cholestatic liver disease, etc.\n* Severe cardiovascular disease patients: those who have been screened for NYHA class III or IV, acute myocardial infarction, unstable angina, large pericardial effusion, severe arrhythmia, or abnormal electrocardiogram within the previous 6 months and are deemed unsuitable for inclusion by the researchers.\n* Screening for individuals who have been in the active stage of malignant tumors within the previous 12 months, or have received radiotherapy, chemotherapy, targeted therapy, and immunotherapy during this period.\n* There are uncontrollable or drug-induced fungal, bacterial, viral, or other infections, including tuberculosis patients undergoing anti tuberculosis treatment, patients known to be infected with human immunodeficiency virus (HIV), etc.\n* Hypertensive patients who cannot achieve good control with drug therapy: systolic blood pressure ≥ 180mmHg, or diastolic blood pressure ≥ 110mmHg.\n* Patients who are currently using glucocorticoids and immunosuppressants.\n* Patients with mental illness or cognitive impairment who are unable to correctly understand VAS scores and describe their own feelings.\n* Received or adjusted antihistamines, systemic or local corticosteroids (excluding ear or eye preparations), calcineurin inhibitors, gabapentin, pregabalin, and other restricted combination drugs within 7 days prior to screening, or expected to change their treatment regimen during the study period.\n* Started receiving or adjusting drugs that may affect the assessment of itch relief efficacy within 2 weeks prior to screening, including but not limited to antipsychotics, sedatives, selective serotonin reuptake inhibitors (SSRIs), anxiolytics, or tricyclic antidepressants, or expected to change their treatment regimen during the study period.\n* Individuals with a history of drug abuse, drug dependence, or alcohol abuse within the past 12 months prior to screening.\n* Select patients who have received phototherapy for pruritus within the previous month.\n* Individuals who have used opioid receptor agonists or antagonists within the past 2 weeks prior to screening.\n* Individuals with a known history of allergy to opioid drugs, or those who are allergic to test drug excipients.\n* Individuals who have participated in other clinical studies and used the investigational drug or medical device within the 28 days prior to screening, or whose investigational drug is within 5 half lives prior to screening.\n* Pregnant women, breastfeeding women, patients with positive pregnancy tests, or those who do not agree to use contraception during the study period.\n* Other patients deemed unsuitable by researchers to participate in this clinical study.",{"count":533,"type":22},150,[86],"This is a randomized, open-label, multi-center clinical study aimed at evaluating the efficacy and safety of 12 weeks of nalfurafine hydrochloride administration in the treatment of pruritus in patients undergoing maintenance hemodialysis.",[537],"Chronic Kidney Disease-Associated Pruritus in Hemodialysis","2026-06-14",{"date":540,"type":37},"2026-06-16",{"date":522,"type":22},{"date":543,"type":22},"2028-12-31",{"name":43,"class":44},{"id":546,"slug":547,"hasResults":12,"nctId":548,"briefTitle":549,"officialTitle":550,"acronym":4,"eligibilityCriteria":551,"healthyVolunteers":12,"sex":17,"minAge":106,"maxAge":54,"enrollmentInfo":552,"targetDuration":4,"studyType":57,"phases":554,"briefSummary":555,"conditions":556,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":559,"lastUpdatePostDateStruct":560,"startDateStruct":562,"completionDateStruct":563,"leadSponsor":565,"locationsCount":45},"100636813","phase-1-clinical-study-of-the-safety-and-efficacy-of-allogeneic-tcr-enhanced-v2-t-cell-in-patients-with-malignant-tumors-100636813","NCT07570563","Clinical Study of the Safety and Efficacy of Allogeneic TCR-enhanced Vδ2 T Cell in Patients With Malignant Tumors.","A Clinical Study on the Safety and Efficacy of Allogeneic TCR-enhanced Vδ2 T Cell Injection in the Treatment of Patients With Malignant Tumors","Inclusion Criteria:\n\n* Age 18-75 (inclusive).\n* Expected survival time ≥ 3 months.\n* Meets current clinical diagnostic criteria with a confirmed diagnosis of a malignant hematologic tumor or solid tumor, and has failed standard therapy (for solid tumors, at least one evaluable lesion according to RECIST v1.1 is required).\n* Adequate bone marrow reserve and essentially normal liver and kidney function (laboratory tests must meet the following criteria prior to the first allogeneic TCR-enhanced Vδ2 T cell treatment):\n* Hematology: White Blood Cell Count (WBC) ≥ 2.5×10⁹\u002FL, Lymphocyte Count (LY) ≥ 0.8×10⁹\u002FL, Hemoglobin (Hb) ≥ 80 g\u002FL, Platelets (PLT) ≥ 75×10⁹\u002FL.\n* Liver: ALT ≤ 3 × ULN; AST ≤ 3 × ULN; Total Bilirubin ≤ 3.0 × ULN.\n* Kidney: Serum Creatinine ≤ 1.5 × ULN.\n* Cardiac: Left Ventricular Ejection Fraction (LVEF) ≥ 50% as measured by echocardiogram.\n* Pulmonary: Normal oxygen saturation without supplemental oxygen.\n* Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0-1.\n* A negative pregnancy test is required for women of childbearing potential. Both male and female subjects must agree to use effective contraception during the treatment period and for 1 year thereafter.\n* Able to understand the trial requirements and is willing to participate in the clinical study as required.\n* Voluntarily signs the informed consent form for the clinical trial.\n\nExclusion Criteria:\n\n* Known history of allergy, hypersensitivity, intolerance, or contraindication to allogeneic TCR-enhanced Vδ2 T cell or any components of the study drugs (including fludarabine, cyclophosphamide and albumin paclitaxel).\n* Continuous use of immunosuppressants within 1 month prior to allogeneic TCR-enhanced Vδ2 T cell infusion.\n* History of cerebrovascular accident or seizure within 6 months prior to signing the informed consent.\n* Symptomatic brain metastases.\n* Known psychiatric or substance abuse disorders that would compromise compliance with study requirements.\n* Positive for Hepatitis B surface antigen (HBsAg) or Hepatitis B core antibody (HBcAb) with detectable Hepatitis B virus (HBV) DNA levels outside the normal reference range; positive for Hepatitis C virus (HCV) antibody with detectable HCV RNA; positive for Human Immunodeficiency Virus (HIV) antibody; positive for syphilis.\n* Severe cardiac disease, including but not limited to unstable angina, myocardial infarction (within 6 months prior to screening), congestive heart failure (NYHA Class ≥ III), and severe arrhythmia.\n* Active or uncontrolled infection requiring systemic therapy (except for mild urogenital and upper respiratory tract infections).\n* Has not recovered from acute toxic effects of prior therapy (i.e., persisting hematological or organ toxicity ≥ Grade 2 related to prior therapy, excluding abnormalities associated with the study disease and its history).\n* Diagnosed with immunodeficiency.\n* Active infection requiring systemic treatment.\n* Female subjects of childbearing potential planning pregnancy within 2 years after cell infusion; or male subjects whose partners are planning pregnancy within 2 years after cell infusion.\n* Participation in another investigational drug clinical study within 1 month prior to screening.\n* Last anti-tumor therapy administered less than 5 half-lives of the drug prior to planned allogeneic TCR-enhanced Vδ2 T cell infusion.\n* Any other condition deemed by the investigator to make the subject unsuitable for participation in this study.",{"count":553,"type":22},24,[110,256],"The allogeneic TCR-enhanced Vδ2 T cell product is a novel genetically engineered cellular therapeutic. By engineering a specific BTN protein-binding moiety on its cell surface, this product harnesses the intrinsic tumoricidal potential of endogenous Vδ2 T cells and augments BTN protein recognition capability, thereby significantly boosting tumor cell killing potency. Notably, this engineered cell product exhibits no expression of co-stimulatory signaling domains and CD3ζ domains. This design circumvents T cell exhaustion triggered by overactivation and markedly enhances the in vivo persistence of therapeutic cells.\n\nThis is an open, prospective, open-label Phase I\u002FII clinical trial designed to assess the safety and therapeutic efficacy of allogeneic TCR-enhanced Vδ2 T cell injection in patients with relapsed or refractory hematologic malignancies and advanced solid tumors.",[557,558],"Hematologic Malignancy","Solid Tumor","2026-06-05",{"date":561,"type":37},"2026-06-08",{"date":559,"type":37},{"date":564,"type":22},"2031-12-31",{"name":43,"class":44},{"id":567,"slug":568,"hasResults":12,"nctId":569,"briefTitle":570,"officialTitle":571,"acronym":572,"eligibilityCriteria":573,"healthyVolunteers":12,"sex":17,"minAge":106,"maxAge":137,"enrollmentInfo":574,"targetDuration":4,"studyType":57,"phases":575,"briefSummary":576,"conditions":577,"keywords":579,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":582,"lastUpdatePostDateStruct":583,"startDateStruct":585,"completionDateStruct":586,"leadSponsor":587,"locationsCount":45},"100643740","phase-1-human-placenta-derived-3d-mesenchymal-stem-cellsguojianqingke-100643740","NCT07635758","Human Placenta-derived 3D Mesenchymal Stem Cells(Guojianqingke)","A Phase I\u002FIIa Clinical Trial on the Safety, Tolerability, and Preliminary Efficacy of Human Placental-Derived 3D Mesenchymal Stem Cell Injection Administered Via the Intravenous Route in Patients With Acute Ischemic Stroke (AIS): A Randomized, Double-Blind, Placebo-Controlled Study","3D MSC - QK01","Inclusion Criteria:\n\n1. Age ≥18 years and ≤80 years; any gender\n2. Body weight 45-90 kg\n3. Diagnosed with acute ischemic stroke, with onset between 6 and 72 hours (inclusive) prior to enrollment; received thrombolysis or not planned for thrombolysis and no planned thrombectomy\n4. NIHSS score 6-20, with NIHSS item 1a (Level of Consciousness) \\\u003C2\n5. Participant or legally authorized representative able to understand and provide written informed consent\n\nExclusion Criteria:\n\n1. Significant pre-stroke disability (pre-stroke modified Rankin Scale \\[mRS\\] score ≥2)；\n2. History of intracerebral hemorrhage, subarachnoid hemorrhage, or hemorrhagic transformation after this ischemic stroke (imaging re-evaluation before planned dosing shows new bleeding within the infarct area accompanied by neurological deterioration \\[e.g., NIHSS total score increased ≥4 points from admission\\], judged by the investigator as unsuitable for clinical trial participation); or presence of cerebrovascular malformation, multiple sclerosis, severe traumatic brain injury history, encephalitis, or other conditions causing stroke-like symptoms\n3. Uncontrolled systemic diseases, including but not limited to: hypertension (systolic BP \\>180 mmHg and\u002For diastolic BP ≥120 mmHg), diabetes (diabetic acute complications such as ketoacidosis, hyperosmolar hyperglycemic state, lactic acidosis, or hypoglycemic coma within 3 months, or difficult-to-control diabetes \\[blood glucose \\>16.8 mmol\u002FL or \\\u003C2.8 mmol\u002FL\\]), renal disease (eGFR \\\u003C30 mL\u002Fmin\u002F1.73m²), hepatic failure (Child-Pugh Class C), severe heart failure (NYHA Class IV), severe chronic respiratory disease\n4. History of seizure (except secondary epilepsy not currently requiring drug treatment)\n5. History of brain tumor or malignancy within the past 5 years, including concurrent second primary malignancy, except: a) radically excised non-melanoma skin cancer; b) radically treated cervical carcinoma in situ; c) radically treated papillary thyroid carcinoma; d) radically treated localized prostate cancer; e) radically treated ductal carcinoma in situ of the breast\n6. History of any of the following:\n\n   1. Active or uncontrolled autoimmune disease (e.g., antiphospholipid antibody syndrome)\n   2. Protein C or protein S deficiency\n   3. Sickle cell anemia\n   4. Deep vein thrombosis\n   5. Pulmonary embolism\n   6. Cerebrovascular malformation (e.g., moyamoya disease)\n7. Any concomitant disease or physical condition (e.g., severe arthritis, amputation, blindness, severe disability from prior stroke) that, in the investigator's judgment, would significantly interfere with accurate assessment of mRS, NIHSS, or BI scores\n8. Major surgery within the past 30 days (e.g., thoracotomy, cardiac surgery, abdominal surgery, intracranial surgery)\n9. Currently severe illness, including:\n\n   1. Severe heart failure (NYHA Class III-IV)\n   2. Severe febrile illness (any fever within 14 days before dosing requiring systemic anti-infective treatment)\n   3. Primary or secondary immunodeficiency disease, or long-term or recent high-dose immunosuppressant or systemic corticosteroid therapy before screening\n   4. Hemorrhagic disorder or bone marrow transplantation\n   5. Any comorbidity that the investigator believes may shorten survival or limit ability to complete the study\n   6. Uncontrolled depression affecting daily life before stroke, dementia that may affect clinical assessment, or other neurological or psychiatric disorders that the investigator believes may affect study assessment\n10. Uncontrolled active infection; or systemic anti-infective treatment within 7 days before dosing that the investigator assesses may shortly convert to uncontrolled active infection\n11. Organ function meeting any of the following:\n\n    Hematology:\n\n    Absolute neutrophil count (ANC) \\\u003C1.0×10⁹\u002FL Platelets (PLT) \\\u003C75×10⁹\u002FL Hemoglobin (Hb) \\\u003C80 g\u002FL\n\n    Hepatic\u002FRenal Function:\n\n    Alanine aminotransferase (ALT) \\>2.5×ULN Aspartate aminotransferase (AST) \\>2.5×ULN Total bilirubin (TBIL) \\>1.5×ULN Creatinine \\>1.5×ULN\n\n    Coagulation:\n\n    Phase I: Not receiving anticoagulant or antithrombotic therapy: PT and APTT \\>1.25×ULN, INR \\>1.4; Receiving anticoagulant or antithrombotic therapy: PT and APTT \\>1.5×ULN, INR \\>3.0 Phase IIa: Not receiving anticoagulant therapy: APTT \\>2.0×ULN or PT \\>2.0×ULN; Receiving anticoagulant therapy: judged by investigator to have severe bleeding risk\n12. Clinically significant uncorrected electrolyte disturbances (e.g., hyperkalemia, hypernatremia) that the investigator believes may affect study assessment\n13. Unable to undergo head CT\u002FMRI for any reason (e.g., cardiac pacemaker, metal implants, claustrophobia)\n14. History of drug abuse or alcohol abuse within the past year\n15. Allergy to bovine or porcine products, human serum albumin products, or known allergy to gentamicin\n16. Participation in another investigational drug, device study, or stem cell\u002Fimmune cell therapy within 3 months before treatment\n17. History of blood transfusion or vaccination with attenuated\u002Flive vaccine within 3 months before screening\n18. Pregnant or lactating women; or participants with pregnancy plans during the study period, or unwilling to use effective contraception; or females of childbearing potential with positive pregnancy test; or female participants on long-term oral contraceptives (continuous use \\>30 days)\n19. Other reasons deemed by the investigator as unsuitable for participation or inability to complete study procedures (e.g., lack of willingness)",{"count":553,"type":22},[110,256],"This is a Phase I\u002FIIa clinical trial evaluating human placental-derived 3D mesenchymal stem cell (MSC) injection in patients with acute ischemic stroke (AIS). Phase I is a single-dose escalation study to determine the maximum tolerated dose (MTD) and recommended Phase II dose (RP2D). Phase IIa explores preliminary efficacy. Each participant undergoes screening (up to 72 hours before treatment), a single-day treatment period, and follow-up for up to 720 days (24 months).",[578],"Acute Ischemic Stroke",[580,581],"Acute Ischemic Stroke，AIS","mesenchymal stem cells","2026-06-03",{"date":584,"type":37},"2026-06-09",{"date":125,"type":37},{"date":390,"type":22},{"name":43,"class":44},{"id":589,"slug":590,"hasResults":12,"nctId":591,"briefTitle":592,"officialTitle":593,"acronym":4,"eligibilityCriteria":594,"healthyVolunteers":12,"sex":17,"minAge":106,"maxAge":54,"enrollmentInfo":595,"targetDuration":4,"studyType":57,"phases":596,"briefSummary":597,"conditions":598,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":600,"lastUpdatePostDateStruct":601,"startDateStruct":603,"completionDateStruct":605,"leadSponsor":607,"locationsCount":337},"100639986","phase-1-safety-and-efficacy-of-ksvcbd-injection-in-multiple-myeloma-expressing-cd19-andor-bcma-100639986","NCT07620275","Safety and Efficacy of KSVCBD Injection in Multiple Myeloma Expressing CD19 and\u002For BCMA","A Multicenter Clinical Study on the Safety and Efficacy of KSVCBD Injection in the Treatment of Multiple Myeloma With Positive Expression of CD19 and\u002For BCMA","Key Inclusion Criteria:\n\n1. Age 18-75 years (inclusive), any gender.\n2. Subjects must meet the following diagnostic and treatment criteria:\n\n   2.1 According to the IMWG 2014 diagnostic criteria, subjects must have a confirmed diagnosis of multiple myeloma and be in a relapsed or refractory state at screening, while meeting all of the following conditions:\n   * Must have received at least 3 prior lines of MM therapy (including a proteasome inhibitor and an immunomodulatory agent). consecutive cycles of induction chemotherapy, hematopoietic stem cell transplantation, and maintenance therapy are considered as one line of therapy if no disease progression occurs between these treatments. each line of therapy must consist of at least one complete treatment cycle, unless the best response to that regimen was disease progression.\n   * Must have experienced disease progression during or within 12 months after the most recent anti-myeloma therapy. or the subject must have experienced disease progression within the last 6 months and subsequently shown no response to the most recent line of therapy. Lack of response is defined as failure to achieve at least a minimal response (MR) or experiencing disease progression (PD) during treatment.\n\n   2.2 Subjects judged by the investigator to be intolerant to standard therapy may also be included in the study.\n3. Presence of measurable lesions at screening as determined by any of the following criteria:\n\n   * Serum monoclonal paraprotein (M-protein) level ≥ 1.0 g\u002FdL, or urinary M-protein level ≥ 200 mg\u002F24 hours. or\n   * For light chain multiple myeloma without measurable lesions in serum or urine: serum immunoglobulin free light chain level ≥ 10 mg\u002FdL and an abnormal serum immunoglobulin κ\u002Fλ free light chain ratio.\n4. Positive expression of CD19 and\u002For BCMA in tumor tissue confirmed by flow cytometry and\u002For histopathology (previous pathology or flow cytometry diagnosis of CD19 and\u002For BCMA in the patient, as confirmed by the investigator, is acceptable). For subjects who have previously received anti-CD19 and\u002For anti-BCMA therapy, a tumor biopsy should be performed to confirm current positive expression of CD19 and\u002For BCMA.\n5. Toxicities from any prior therapy must be stable and have resolved to ≤ Grade 1 (excluding hematologic toxicities and clinically insignificant toxicities such as alopecia).\n6. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2.\n\nKey Exclusion Criteria:\n\n1. Expected survival \\\u003C 3 months.\n2. History of or concurrent active malignancy. Exceptions include: carcinoma in situ of the cervix that has been cured or with no recurrence for at least 3 years, non-invasive basal cell or squamous cell skin cancer, locally advanced prostate cancer that has received curative treatment, or ductal carcinoma in situ after radical surgery.\n3. Prior allogeneic hematopoietic stem cell transplantation (allo-HSCT) or autologous HSCT within 3 months prior to KSVCBD infusion.\n4. Solitary extramedullary soft tissue plasmacytoma.\n5. Diagnosis of plasma cell leukemia, Waldenström's macroglobulinemia, POEMS syndrome, or primary AL amyloidosis.\n6. Presence of CNS metastasis or symptoms of CNS metastasis.\n7. Receipt of anti-tumor therapy that is still within 5 half-lives prior to the planned KSVCBD infusion.\n8. Presence of uncontrolled active infections.\n9. Positive for human immunodeficiency virus (HIV) antibody, positive for Treponema pallidum antibody, positive for hepatitis B surface antigen (HBsAg) or positive for hepatitis B core antibody (HBcAb) with detectable peripheral blood HBV DNA, or positive for hepatitis C virus (HCV) antibody with detectable HCV RNA. except for infections that the investigator judges can be prevented or controlled with medication.\n10. Known active autoimmune disease requiring systemic treatment.\n11. Known severe allergy to the study drug or any of its components.\n12. Pregnant or breastfeeding women.\n13. Receipt of a live vaccine within 6 weeks prior to enrollment.",{"count":400,"type":22},[110],"KSVCBD injection is an in vivo Chimeric Antigen Receptor T-Cell (CAR-T cell) therapy product. This multicenter, single-arm, open-label, early exploratory clinical study is designed to evaluate the preliminary safety and efficacy of KSVCBD injection in patients with relapsed or refractory (r\u002Fr) multiple myeloma(MM) expressing CD19 and\u002For BCMA.",[599],"Multiple Myeloma","2026-05-27",{"date":602,"type":37},"2026-06-02",{"date":604,"type":22},"2026-06-10",{"date":606,"type":22},"2029-03-15",{"name":43,"class":44},{"id":609,"slug":610,"hasResults":12,"nctId":611,"briefTitle":612,"officialTitle":613,"acronym":4,"eligibilityCriteria":614,"healthyVolunteers":12,"sex":17,"minAge":106,"maxAge":213,"enrollmentInfo":615,"targetDuration":4,"studyType":57,"phases":617,"briefSummary":618,"conditions":619,"keywords":621,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":623,"lastUpdatePostDateStruct":624,"startDateStruct":626,"completionDateStruct":627,"leadSponsor":629,"locationsCount":45},"100637490","early-phase-1-safety-and-efficacy-of-ksvcbd-injection-in-autoimmune-diseases-100637490","NCT07613411","Safety and Efficacy of KSVCBD Injection in Autoimmune Diseases","A Clinical Study to Evaluate the Safety and Efficacy of KSVCBD Injection in Patients With Autoimmune Diseases","Inclusion Criteria:\n\n1. Age 18-65 years (inclusive), any gender.\n2. Subjects diagnosed with the following autoimmune disease: moderate\u002Fsevere refractory Systemic Lupus Erythematosus, elapsed\u002Frefractory Systemic Sclerosis, relapsed\u002Frefractory ANCA-Associated Vasculitis, refractory Idiopathic Inflammatory Myopathy, active Sjögren's Syndrome, chronic\u002Frefractory Immune Thrombocytopenia, refractory Antiphospholipid Syndrome, relapsed\u002Frefractory pemphigus, relapsed\u002Frefractory IgG4-Related Disease.\n3. Having adequate organ function as required by the protocol.:\n4. Voluntarily adhere to the contraception requirements as specified in the protocol.\n5. Willing to comply with all study procedures and voluntarily participate in this study and sign the informed consent form (ICF).\n\nExclusion Criteria:\n\n1. Previous or current active malignancy, including patients with cancer-associated polymyositis\u002Fdermatomyositis. Exceptions are cured or relapse-free for at least 3 years: cervical carcinoma in situ, non-invasive basal cell or squamous cell skin cancer, locally advanced prostate cancer after radical treatment, or ductal carcinoma in situ after radical surgery.\n2. Severe pulmonary disease within the past 1 year, such as moderate\u002Fsevere pulmonary arterial hypertension (pulmonary artery systolic pressure \\>50 mmHg on echocardiography), requirement for oxygen therapy via reservoir mask or non-invasive\u002Finvasive ventilator support at screening.\n3. Use of any of the protocol specified drugs or treatments within the specified timeframes.\n4. History or current symptoms of severe central nervous system (CNS) disease within the past 6 months.\n5. Known severe allergy to the study drug or any of its components.\n6. Presence of uncontrolled fungal, bacterial, or viral infection, or other infections considered by the investigator to make the subject unsuitable for participation.\n7. History of major organ transplant or hematopoietic stem cell\u002Fbone marrow transplantation.\n8. History of other autoimmune diseases requiring systemic treatment, other than the target indication.\n9. History of non-IIM conditions such as drug induced myopathy, HIV associated myopathy, thyroid myopathy, or family history of myopathy.\n10. Pregnant or breastfeeding women.\n11. Use of any live vaccines within 6 weeks before enrollment.\n12. Participation in another interventional clinical study and receipt of an active investigational drug within 3 months prior to signing the ICF, or intention to participate in another clinical trial or receive treatment for autoimmune diseases outside the protocol during the entire study period.\n13. Psychiatric disorders with depression or suicidal tendencies.\n14. Any other factors considered by the investigator to make the subject unsuitable for enrollment or to affect the subject's participation or completion of the study.",{"count":616,"type":22},60,[488],"KSVCBD injection is an in vivo Chimeric Antigen Receptor T-Cell (CAR-T cell) therapy product. This single-arm, open-label, early exploratory clinical study is designed to evaluate the safety and preliminary efficacy of KSVCBD injection in patients with Autoimmune Diseases.",[620],"Autoimmune Diseases",[620,622],"Immunotherapy","2026-05-22",{"date":625,"type":37},"2026-05-29",{"date":125,"type":22},{"date":628,"type":22},"2029-03-31",{"name":43,"class":44},""]